{
  "cells": [
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "cTTl7oIR9i4Q",
        "outputId": "82ce8dd5-849e-4699-e97a-26f95f781692"
      },
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "Requirement already satisfied: pip in /usr/local/lib/python3.10/dist-packages (23.1.2)\n",
            "Collecting pip\n",
            "  Downloading pip-23.3.1-py3-none-any.whl (2.1 MB)\n",
            "\u001b[2K     \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m2.1/2.1 MB\u001b[0m \u001b[31m27.8 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hInstalling collected packages: pip\n",
            "  Attempting uninstall: pip\n",
            "    Found existing installation: pip 23.1.2\n",
            "    Uninstalling pip-23.1.2:\n",
            "      Successfully uninstalled pip-23.1.2\n",
            "Successfully installed pip-23.3.1\n",
            "Collecting openai==0.28\n",
            "  Downloading openai-0.28.0-py3-none-any.whl.metadata (13 kB)\n",
            "Requirement already satisfied: requests>=2.20 in /usr/local/lib/python3.10/dist-packages (from openai==0.28) (2.31.0)\n",
            "Requirement already satisfied: tqdm in /usr/local/lib/python3.10/dist-packages (from openai==0.28) (4.66.1)\n",
            "Requirement already satisfied: aiohttp in /usr/local/lib/python3.10/dist-packages (from openai==0.28) (3.9.1)\n",
            "Requirement already satisfied: charset-normalizer<4,>=2 in /usr/local/lib/python3.10/dist-packages (from requests>=2.20->openai==0.28) (3.3.2)\n",
            "Requirement already satisfied: idna<4,>=2.5 in /usr/local/lib/python3.10/dist-packages (from requests>=2.20->openai==0.28) (3.6)\n",
            "Requirement already satisfied: urllib3<3,>=1.21.1 in /usr/local/lib/python3.10/dist-packages (from requests>=2.20->openai==0.28) (2.0.7)\n",
            "Requirement already satisfied: certifi>=2017.4.17 in /usr/local/lib/python3.10/dist-packages (from requests>=2.20->openai==0.28) (2023.11.17)\n",
            "Requirement already satisfied: attrs>=17.3.0 in /usr/local/lib/python3.10/dist-packages (from aiohttp->openai==0.28) (23.1.0)\n",
            "Requirement already satisfied: multidict<7.0,>=4.5 in /usr/local/lib/python3.10/dist-packages (from aiohttp->openai==0.28) (6.0.4)\n",
            "Requirement already satisfied: yarl<2.0,>=1.0 in /usr/local/lib/python3.10/dist-packages (from aiohttp->openai==0.28) (1.9.3)\n",
            "Requirement already satisfied: frozenlist>=1.1.1 in /usr/local/lib/python3.10/dist-packages (from aiohttp->openai==0.28) (1.4.0)\n",
            "Requirement already satisfied: aiosignal>=1.1.2 in /usr/local/lib/python3.10/dist-packages (from aiohttp->openai==0.28) (1.3.1)\n",
            "Requirement already satisfied: async-timeout<5.0,>=4.0 in /usr/local/lib/python3.10/dist-packages (from aiohttp->openai==0.28) (4.0.3)\n",
            "Downloading openai-0.28.0-py3-none-any.whl (76 kB)\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m76.5/76.5 kB\u001b[0m \u001b[31m2.3 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hInstalling collected packages: openai\n",
            "\u001b[31mERROR: pip's dependency resolver does not currently take into account all the packages that are installed. This behaviour is the source of the following dependency conflicts.\n",
            "llmx 0.0.15a0 requires cohere, which is not installed.\n",
            "llmx 0.0.15a0 requires tiktoken, which is not installed.\u001b[0m\u001b[31m\n",
            "\u001b[0mSuccessfully installed openai-0.28.0\n",
            "\u001b[33mWARNING: Running pip as the 'root' user can result in broken permissions and conflicting behaviour with the system package manager. It is recommended to use a virtual environment instead: https://pip.pypa.io/warnings/venv\u001b[0m\u001b[33m\n",
            "\u001b[0m"
          ]
        }
      ],
      "source": [
        "!pip install --upgrade pip\n",
        "!pip install openai==0.28"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "kezd-BpAEmkL",
        "outputId": "cbc6f8e7-daf3-46db-8db6-a77a53bd3fa3"
      },
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "Drive already mounted at /content/drive; to attempt to forcibly remount, call drive.mount(\"/content/drive\", force_remount=True).\n"
          ]
        }
      ],
      "source": [
        "\n",
        "from google.colab import drive\n",
        "\n",
        "# Mount Google Drive\n",
        "drive.mount('/content/drive')"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "UuV1tq9a9le_"
      },
      "outputs": [],
      "source": [
        "\n",
        "import openai\n",
        "openai.api_key = \"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\"\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "38y1qbhV9oVl"
      },
      "outputs": [],
      "source": [
        "def prompt1(original_question):\n",
        "  instruction = \"\"\"\n",
        "  You are a medical expert who is preparing questions for the USMLE-step 2-CK exam.\n",
        "  \"\"\"\n",
        "\n",
        "  prompt0 = \"Why is the given option the correct answer and why are the other options wrong?\"\n",
        "  input_titles = original_question + \"\\n\" + prompt0\n",
        "  response = openai.ChatCompletion.create(\n",
        "      model=\"gpt-4\",\n",
        "      messages=[\n",
        "          {\"role\": \"system\", \"content\": instruction},\n",
        "          {\"role\": \"user\", \"content\": input_titles},\n",
        "      ],\n",
        "      temperature=0\n",
        "  )\n",
        "\n",
        "  print(response[\"choices\"][0][\"message\"][\"content\"])\n",
        "  print(type(response[\"choices\"][0][\"message\"][\"content\"]))\n",
        "  return response[\"choices\"][0][\"message\"][\"content\"]"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "7yE1iuKL9qva"
      },
      "outputs": [],
      "source": [
        "def prompt2(original_question, data1):\n",
        "  instruction = \"\"\"\n",
        "  You are a medical expert who is preparing questions for the USMLE-step 2-CK exam.\n",
        "  \"\"\"\n",
        "  new_prompt = \"Generate a question for USMLE Step 2 CK with answer and explanation using a similar format and a similar difficulty level as the above. For the multiple choice options, use the generated question context as distractors\"\n",
        "  input_titles1 = original_question + \"\\n\" + data1 + \"\\n\" + new_prompt\n",
        "  response1 = openai.ChatCompletion.create(\n",
        "      model=\"gpt-4\",\n",
        "      messages=[\n",
        "          {\"role\": \"system\", \"content\": instruction},\n",
        "          {\"role\": \"user\", \"content\": input_titles1},\n",
        "      ],\n",
        "      temperature=0\n",
        "  )\n",
        "\n",
        "  print(response1[\"choices\"][0][\"message\"][\"content\"])\n",
        "  return response1[\"choices\"][0][\"message\"][\"content\"]"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "Hq-FqQt9Rmg9",
        "outputId": "6abb9f24-2dda-4d0d-a21d-04c03b3c3c74"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Contents of 1.json:\n",
            "{'question': 'A 27-year-old man is brought to a mountain base camp at 4000 m (13,100 ft) above sea level because he has had a 2-hour history of confusion, difficulties walking, and decreased responsiveness. He has been participating in a 5-day hiking trip in which the group has ascended 1500 m (4900 ft) from the base camp in 2 days. This morning, the third day of the trip, the patient was found in his tent unable to respond to simple questions and having wet himself. The night before, he reported headaches, dizziness, and nausea. He appears lethargic. Temperature is 37.5°C (99.5°F), pulse is 85/min, respirations are 20/min, and blood pressure is 135/85 mm Hg. Pulse oximetry on room air shows an oxygen saturation of 89%. Neurological examination shows slurred speech and an ataxic gait. Kernig sign is absent. Further diagnostic studies cannot be performed due to limited medical equipment. The most appropriate initial step in management is the administration of which of the following?', 'hint': 'Headaches, dizziness, and nausea while at an altitude over 2500 m (8000 ft) above sea level suggests acute mountain sickness (AMS). Altered consciousness, ataxia, and urinary incontinence are consistent with high-altitude cerebral edema (HACE), a life-threatening complication of AMS.', 'options': [{'option': 'A\\nNifedipine', 'percent': '2%', 'answer': 'Nifedipine is used in the prevention and treatment of high altitude pulmonary edema (HAPE), a complication of AMS. While the severe hypoxemia in HAPE may lead to concomitant HACE, this patient shows no signs and symptoms of HAPE, such as cough, shortness of breath, cyanosis, tachypnea, tachycardia, and crackles or wheezing on pulmonary auscultation.', 'image': None}, {'option': 'B\\nHaloperidol', 'percent': '0%', 'answer': \"Haloperidol is used in the treatment of acute psychosis. While some of this patient's symptoms are also seen in acute psychosis (confusion, decreased responsiveness, slurred speech), loss of bladder control, headaches, dizziness, nausea, and ataxia are not expected. Moreover, typical symptoms of acute psychosis, such as hallucinations and delusions, are not present. Finally, this patient has no reported history of mental illness that could lead to acute psychosis (e.g., schizophrenia, bipolar disorder).\", 'image': None}, {'option': 'C\\nMannitol', 'percent': '14%', 'answer': 'Mannitol is used in the treatment of cerebral edema. While this drug can be used to lower intracranial pressure in severe cases of HACE, it is not the initial treatment of choice.', 'image': None}, {'option': 'D\\nAcetazolamide', 'percent': '68%', 'answer': 'Acetazolamide accelerates acclimatization to high altitude via multiple mechanisms (e.g., increased renal excretion of bicarbonate, increased ventilation and oxygenation) and is, therefore, used in the prevention and treatment of AMS. Acetazolamide is not, however, effective in the treatment of HACE.', 'image': None}, {'option': 'E\\nDexamethasone', 'percent': '15%', 'answer': \"Dexamethasone is a rescue medication for HACE that may significantly improve the patient's condition, and it should be administered as soon as this complication is suspected. However, dexamethasone does not replace the need for immediate descent to a lower altitude, which is the definitive treatment. Oxygen supplementation and portable hyperbaric therapy are further lifesaving measures if immediate evacuation is not possible. The most effective preventive measure for AMS and HACE is a slow ascent.\\nEnvironmental pathology\", 'image': None}], 'correct_answer': \"E\\nDexamethasone\\n15%\\nDexamethasone is a rescue medication for HACE that may significantly improve the patient's condition, and it should be administered as soon as this complication is suspected. However, dexamethasone does not replace the need for immediate descent to a lower altitude, which is the definitive treatment. Oxygen supplementation and portable hyperbaric therapy are further lifesaving measures if immediate evacuation is not possible. The most effective preventive measure for AMS and HACE is a slow ascent.\\nEnvironmental pathology\\nGIVE FEEDBACK\", 'tag': 'emergency-medicine-adult-and-pediatric,pulmonary-and-critical-care-medicine,neurology'}\n",
            "The correct answer is Dexamethasone. This patient's symptoms of confusion, difficulties walking, and decreased responsiveness, along with the history of rapid ascent to high altitude, are indicative of high-altitude cerebral edema (HACE), a life-threatening complication of acute mountain sickness (AMS). Dexamethasone is a rescue medication for HACE that can significantly improve the patient's condition. However, it does not replace the need for immediate descent to a lower altitude, which is the definitive treatment. \n",
            "\n",
            "The other options are incorrect for the following reasons:\n",
            "\n",
            "- Nifedipine is used in the prevention and treatment of high altitude pulmonary edema (HAPE), a complication of AMS. This patient shows no signs and symptoms of HAPE, such as cough, shortness of breath, cyanosis, tachypnea, tachycardia, and crackles or wheezing on pulmonary auscultation.\n",
            "\n",
            "- Haloperidol is used in the treatment of acute psychosis. While some of this patient's symptoms are also seen in acute psychosis (confusion, decreased responsiveness, slurred speech), loss of bladder control, headaches, dizziness, nausea, and ataxia are not expected. Moreover, typical symptoms of acute psychosis, such as hallucinations and delusions, are not present. \n",
            "\n",
            "- Mannitol is used in the treatment of cerebral edema. While this drug can be used to lower intracranial pressure in severe cases of HACE, it is not the initial treatment of choice.\n",
            "\n",
            "- Acetazolamide accelerates acclimatization to high altitude via multiple mechanisms and is used in the prevention and treatment of AMS. However, it is not effective in the treatment of HACE.\n",
            "<class 'str'>\n",
            "{\"question\": \"A 35-year-old woman is brought to the emergency department with a 3-hour history of severe chest pain and shortness of breath. She recently returned from a long-haul flight. On examination, she is anxious, tachypneic, and tachycardic. Her oxygen saturation is 90% on room air. A chest X-ray shows no abnormalities. An ECG shows sinus tachycardia but no signs of ischemia. The most appropriate initial step in management is the administration of which of the following?\", \"hint\": \"The patient's symptoms and recent long-haul flight suggest a pulmonary embolism (PE). The initial management of PE involves anticoagulation to prevent further clot formation.\", \"options\": [{\"option\": \"A\\nFurosemide\", \"percent\": \"5%\", \"answer\": \"Furosemide is a diuretic used in the management of fluid overload conditions such as heart failure. It is not indicated in the initial management of a suspected pulmonary embolism.\", \"image\": null}, {\"option\": \"B\\nNitroglycerin\", \"percent\": \"10%\", \"answer\": \"Nitroglycerin is used in the management of angina and acute coronary syndromes. While chest pain is a symptom of both PE and acute coronary syndromes, the patient's recent long-haul flight and tachypnea are more suggestive of a PE.\", \"image\": null}, {\"option\": \"C\\nHeparin\", \"percent\": \"70%\", \"answer\": \"Heparin is an anticoagulant that is used in the initial management of a suspected pulmonary embolism. It prevents further clot formation while the diagnosis is being confirmed.\", \"image\": null}, {\"option\": \"D\\nAlbuterol\", \"percent\": \"10%\", \"answer\": \"Albuterol is a bronchodilator used in the management of asthma and COPD. It is not indicated in the initial management of a suspected pulmonary embolism.\", \"image\": null}, {\"option\": \"E\\nAmiodarone\", \"percent\": \"5%\", \"answer\": \"Amiodarone is an antiarrhythmic medication. It is not indicated in the initial management of a suspected pulmonary embolism.\", \"image\": null}], \"correct_answer\": \"C\\nHeparin\\n70%\\nHeparin is an anticoagulant that is used in the initial management of a suspected pulmonary embolism. It prevents further clot formation while the diagnosis is being confirmed.\", \"tag\": \"emergency-medicine-adult-and-pediatric,pulmonary-and-critical-care-medicine,cardiology\"}\n",
            "\n",
            "The correct answer is Heparin. This patient's symptoms of severe chest pain, shortness of breath, and recent long-haul flight are suggestive of a pulmonary embolism (PE). The initial management of PE involves anticoagulation with Heparin to prevent further clot formation.\n",
            "\n",
            "The other options are incorrect for the following reasons:\n",
            "\n",
            "- Furosemide is a diuretic used in the management of fluid overload conditions such as heart failure. It is not indicated in the initial management of a suspected pulmonary embolism.\n",
            "\n",
            "- Nitroglycerin is used in the management of angina and acute coronary syndromes. While chest pain is a symptom of both PE and acute coronary syndromes, the patient's recent long-haul flight and tachypnea are more suggestive of a PE.\n",
            "\n",
            "- Albuterol is a bronchodilator used in the management of asthma and COPD. It is not indicated in the initial management of a suspected pulmonary embolism.\n",
            "\n",
            "- Amiodarone is an antiarrhythmic medication. It is not indicated in the initial management of a suspected pulmonary embolism.\n",
            "Output string has been stored in '/content/drive/My Drive/results/d5-ans/output_1.json.txt'\n",
            "\n",
            "\n",
            "Contents of 169.json:\n",
            "{'question': 'A 56-year-old man comes to the emergency department because of a 1-day history of progressive swelling and pain in his left calf. He does not have shortness of breath or chest pain. He has hypertension and chronic kidney disease. Current medications include enalapril, aspirin, simvastatin, and vitamin D. His temperature is 38°C (100.4°F), pulse is 84/min, and blood pressure is 135/92 mm Hg. Physical examination shows tenderness and swelling of the left lower extremity. A venous Doppler ultrasonography shows a thrombus in the left popliteal vein. Treatment with unfractionated heparin is begun. Two days later, physical examination shows improvement of symptoms. Laboratory studies at admission and 2 days after admission show:\\nAdmission Two days after admission\\nHemoglobin 11.2 g/dL 11.1 g/dL\\nLeukocyte count 5500/mm3 6100/mm3\\nPlatelet count 230,000/mm3 170,000/mm3\\nSerum\\nProthrombin time 12 seconds 13 seconds\\nPartial thromboplastin time 30 seconds 55 seconds\\nEstimated glomerular filtration rate 29 mL/min/1.73 m2 28 mL/min/1.73 m2\\nWhich of the following is the most appropriate next step in management?', 'hint': 'This patient was diagnosed with deep vein thrombosis (DVT) and subsequently started on unfractionated heparin (UFH). Laboratory studies showing a < 30% decrease in platelet count in the first 5 days after initiation of treatment with UFH is highly suggestive of nonimmune heparin-associated thrombocytopenia, formerly known as type 1 heparin-induced thrombocytopenia (HIT).', 'options': [{'option': 'A\\nSwitch to enoxaparin', 'percent': '22%', 'answer': \"Switching to enoxaparin would be a reasonable option to complete this patient's DVT treatment regimen in an outpatient setting. However, because enoxaparin is primarily eliminated via the kidneys, it is contraindicated if the estimated GFR is < 30 mL/min. Impaired kidney function can predispose to supratherapeutic anticoagulation and bleeding. Therefore, this patient, who has an estimated GFR of 28 mL/min/1.73 m2, is not a candidate for enoxaparin therapy.\", 'image': None}, {'option': 'B\\nContinue unfractionated heparin', 'percent': '24%', 'answer': 'This patient should continue heparin therapy to maintain an aPTT 1.5–2.5 times normal until he begins a suitable longer-term anticoagulant to fully treat his DVT. When heparin is initiated, a baseline platelet count needs to be established in order to monitor for HIT. Nonimmune heparin-associated thrombocytopenia, which manifests with a transient, mild reduction in platelet count as a result of the direct induction of platelet aggregation by heparin, is a common condition that occurs in approx. 10–30% of patients treated with heparin; it poses negligible risk for thrombosis, and is self-limiting.\\n\\nSee “Nonimmune heparin-associated thrombocytopenia vs. heparin-induced thrombocytopenia” table.\\nHeparin-induced thrombocytopenia', 'image': None}, {'option': 'C\\nSwitch to warfarin', 'percent': '15%', 'answer': \"Switching to warfarin as a means of providing longer-term anticoagulation for the treatment of the patient's DVT would be reasonable. However, abruptly stopping heparin and switching to warfarin is dangerous because of the transient hypercoagulable state that follows the initiation of therapy with warfarin. In order to prevent new clot formation during this time, heparin is administered continuously along with warfarin until a therapeutic international normalized ratio (INR) is attained.\", 'image': None}, {'option': 'D\\nDiscontinue anticoagulation', 'percent': '5%', 'answer': 'Discontinuing all anticoagulation would be inappropriate for this patient, as his newly diagnosed DVT requires treatment. Most guidelines stipulate 3 months of anticoagulation for first-time DVT, but some patients may require even longer treatment.', 'image': None}, {'option': 'E\\nSwitch to argatroban', 'percent': '34%', 'answer': \"Switching to argatroban would be indicated if this patient developed type 2 HIT. This patient's drop in platelets should raise suspicion for type 2 HIT. However, his platelets have only dropped by 25%, making type 2 HIT unlikely, as it usually manifests with > 50% reduction in platelet count. In addition, the onset of HIT is typically 5–14 days after heparin therapy has begun. Because he has only been receiving treatment for the past 2 days, type 2 HIT is even less likely; switching to argatroban would not be appropriate.\", 'image': None}], 'correct_answer': 'B\\nContinue unfractionated heparin\\n24%\\nThis patient should continue heparin therapy to maintain an aPTT 1.5–2.5 times normal until he begins a suitable longer-term anticoagulant to fully treat his DVT. When heparin is initiated, a baseline platelet count needs to be established in order to monitor for HIT. Nonimmune heparin-associated thrombocytopenia, which manifests with a transient, mild reduction in platelet count as a result of the direct induction of platelet aggregation by heparin, is a common condition that occurs in approx. 10–30% of patients treated with heparin; it poses negligible risk for thrombosis, and is self-limiting.\\n\\nSee “Nonimmune heparin-associated thrombocytopenia vs. heparin-induced thrombocytopenia” table.\\nHeparin-induced thrombocytopenia\\nGIVE FEEDBACK', 'tag': 'hematology,emergency-medicine-adult-and-pediatric,nephrology-and-hypertension,lab-interpretation'}\n",
            "The correct answer is to continue unfractionated heparin. This patient's laboratory studies show a decrease in platelet count of less than 30% within the first 5 days of initiating heparin therapy, which is suggestive of nonimmune heparin-associated thrombocytopenia, formerly known as type 1 heparin-induced thrombocytopenia (HIT). This condition is common, occurring in approximately 10-30% of patients treated with heparin, and is self-limiting. It poses a negligible risk for thrombosis. Therefore, the patient should continue heparin therapy to maintain an aPTT 1.5–2.5 times normal until he begins a suitable longer-term anticoagulant to fully treat his DVT.\n",
            "\n",
            "Option A, switching to enoxaparin, is incorrect because enoxaparin is primarily eliminated via the kidneys and is contraindicated if the estimated GFR is < 30 mL/min. This patient's estimated GFR is 28 mL/min/1.73 m2, so he is not a candidate for enoxaparin therapy.\n",
            "\n",
            "Option C, switching to warfarin, is incorrect because abruptly stopping heparin and switching to warfarin can lead to a transient hypercoagulable state. Heparin should be administered continuously along with warfarin until a therapeutic international normalized ratio (INR) is attained.\n",
            "\n",
            "Option D, discontinuing anticoagulation, is incorrect because this patient's newly diagnosed DVT requires treatment. Most guidelines stipulate 3 months of anticoagulation for first-time DVT.\n",
            "\n",
            "Option E, switching to argatroban, is incorrect because this would be indicated if the patient developed type 2 HIT. However, this patient's platelets have only dropped by 25%, making type 2 HIT unlikely. Furthermore, the onset of HIT is typically 5–14 days after heparin therapy has begun, and this patient has only been receiving treatment for the past 2 days.\n",
            "<class 'str'>\n",
            "{\"question\": \"A 65-year-old woman with a history of hypertension and type 2 diabetes mellitus presents to the emergency department with a 2-day history of progressive swelling and pain in her right calf. She denies any shortness of breath or chest pain. Her current medications include metformin, lisinopril, aspirin, and atorvastatin. Her temperature is 37.8°C (100°F), pulse is 88/min, and blood pressure is 140/90 mm Hg. Physical examination shows tenderness and swelling of the right lower extremity. A venous Doppler ultrasonography shows a thrombus in the right popliteal vein. Treatment with unfractionated heparin is initiated. Two days later, physical examination shows improvement of symptoms. Laboratory studies at admission and 2 days after admission show:\\nAdmission Two days after admission\\nHemoglobin 12.2 g/dL 12.1 g/dL\\nLeukocyte count 6000/mm3 6500/mm3\\nPlatelet count 250,000/mm3 190,000/mm3\\nSerum\\nProthrombin time 13 seconds 14 seconds\\nPartial thromboplastin time 32 seconds 57 seconds\\nEstimated glomerular filtration rate 35 mL/min/1.73 m2 34 mL/min/1.73 m2\\nWhich of the following is the most appropriate next step in management?\", \"hint\": \"This patient was diagnosed with deep vein thrombosis (DVT) and subsequently started on unfractionated heparin (UFH). Laboratory studies showing a < 30% decrease in platelet count in the first 5 days after initiation of treatment with UFH is highly suggestive of nonimmune heparin-associated thrombocytopenia, formerly known as type 1 heparin-induced thrombocytopenia (HIT).\", \"options\": [{\"option\": \"A\\nSwitch to enoxaparin\", \"percent\": \"20%\", \"answer\": \"Switching to enoxaparin would be a reasonable option to complete this patient's DVT treatment regimen in an outpatient setting. However, because enoxaparin is primarily eliminated via the kidneys, it is contraindicated if the estimated GFR is < 30 mL/min. This patient's estimated GFR is 34 mL/min/1.73 m2, so she is a candidate for enoxaparin therapy, but the decrease in platelet count suggests nonimmune heparin-associated thrombocytopenia, which is self-limiting and does not require a change in therapy.\", \"image\": null}, {\"option\": \"B\\nContinue unfractionated heparin\", \"percent\": \"25%\", \"answer\": \"This patient should continue heparin therapy to maintain an aPTT 1.5–2.5 times normal until she begins a suitable longer-term anticoagulant to fully treat her DVT. When heparin is initiated, a baseline platelet count needs to be established in order to monitor for HIT. Nonimmune heparin-associated thrombocytopenia, which manifests with a transient, mild reduction in platelet count as a result of the direct induction of platelet aggregation by heparin, is a common condition that occurs in approx. 10–30% of patients treated with heparin; it poses negligible risk for thrombosis, and is self-limiting.\", \"image\": null}, {\"option\": \"C\\nSwitch to warfarin\", \"percent\": \"15%\", \"answer\": \"Switching to warfarin as a means of providing longer-term anticoagulation for the treatment of the patient's DVT would be reasonable. However, abruptly stopping heparin and switching to warfarin is dangerous because of the transient hypercoagulable state that follows the initiation of therapy with warfarin. In order to prevent new clot formation during this time, heparin is administered continuously along with warfarin until a therapeutic international normalized ratio (INR) is attained.\", \"image\": null}, {\"option\": \"D\\nDiscontinue anticoagulation\", \"percent\": \"5%\", \"answer\": \"Discontinuing all anticoagulation would be inappropriate for this patient, as her newly diagnosed DVT requires treatment. Most guidelines stipulate 3 months of anticoagulation for first-time DVT, but some patients may require even longer treatment.\", \"image\": null}, {\"option\": \"E\\nSwitch to argatroban\", \"percent\": \"35%\", \"answer\": \"Switching to argatroban would be indicated if this patient developed type 2 HIT. However, this patient's platelets have only dropped by 24%, making type 2 HIT unlikely. In addition, the onset of HIT is typically 5–14 days after heparin therapy has begun. Because she has only been receiving treatment for the past 2 days, type 2 HIT is even less likely; switching to argatroban would not be appropriate.\", \"image\": null}], \"correct_answer\": \"B\\nContinue unfractionated heparin\\n25%\\nThis patient should continue heparin therapy to maintain an aPTT 1.5–2.5 times normal until she begins a suitable longer-term anticoagulant to fully treat her DVT. When heparin is initiated, a baseline platelet count needs to be established in order to monitor for HIT. Nonimmune heparin-associated thrombocytopenia, which manifests with a transient, mild reduction in platelet count as a result of the direct induction of platelet aggregation by heparin, is a common condition that occurs in approx. 10–30% of patients treated with heparin; it poses negligible risk for thrombosis, and is self-limiting.\", \"tag\": \"hematology,emergency-medicine-adult-and-pediatric,nephrology-and-hypertension,lab-interpretation\"}\n",
            "Output string has been stored in '/content/drive/My Drive/results/d5-ans/output_169.json.txt'\n",
            "\n",
            "\n",
            "Contents of 143.json:\n",
            "{'question': 'A 72-year-old man with congestive heart failure comes to the office because of a 1-year history of shortness of breath and fatigue. He says that he has to take breaks from his usual daily activities like cooking or cleaning to catch his breath. Six months ago, he was hospitalized for acute decompensation of heart failure and his medication was adjusted. He says that he has had difficulties remembering his medication regimen. He has a history of hypertension and type 2 diabetes mellitus. Medications include hydrochlorothiazide, spironolactone, and metformin. He is 165 cm (5 ft 5 in) tall and weighs 84 kg (185 lb); BMI is 31 kg/m2. Pulse is 89/min, respirations are 20/min, and blood pressure is 135/83 mm Hg. Physical examination shows 2+ pitting pretibial edema bilaterally. Auscultation of the lungs discloses bibasilar mild crackles. Transthoracic echocardiography shows increased sizes of the left atrium and ventricle, diastolic dysfunction, and a left ventricular ejection fraction of approximately 0.55. The physician has recently read a pharmaceutical advertisement for a new drug for heart failure called MelliFly and considers prescribing this medication to the patient. Based on the pharmaceutical advertisement shown, which of the following statements about MelliFly is most appropriate with regard to this patient?', 'hint': \"This patient has heart failure with marked limitations of physical activity (i.e., NYHA class III). When prescribing a medication to a patient, the physician should follow a systematic approach and first consider the patient's individual problem.\", 'options': [{'option': \"A\\nMelliFly should not be prescribed because of potential drug interactions with this patient's other medications\", 'percent': '7%', 'answer': 'Safety concerns (e.g., potential interactions) should be taken into account when prescribing a drug. Pharmaceutical advertisements typically feature a safety warnings box that includes information about potential drug interactions and important risks, which should be weighed against the potential benefits of the drug. This patient takes a thiazide diuretic, an aldosterone receptor antagonist, and the biguanide metformin, none of which is mentioned in the safety warnings box of the advertisement.', 'image': '143.jpg'}, {'option': 'B\\nMelliFly should be prescribed to this patient because of its simple dosing regimen', 'percent': '7%', 'answer': 'The simplicity of a treatment regimen should be taken into account when prescribing a drug. This patient has difficulties remembering his regimen and may benefit from a once-daily medication. However, another aspect of the drug has to be evaluated before considering the dosing regimen.', 'image': '143.jpg'}, {'option': \"C\\nMelliFly should not be prescribed because the advertisement does not feature this patient's clinical syndrome\", 'percent': '48%', 'answer': \"This patient has a history of congestive heart failure and an ejection fraction (EF) of 55%, which indicates that he has heart failure with preserved EF. The advertisement states that the medicine is targeted at patients with heart failure with reduced EF (i.e., with an EF of < 40%). The medication does not address this patient's specific condition, so it would not be appropriate to prescribe it.\\n\\nAfter a clear definition of a patient's problem (e.g., “congestive heart failure with preserved EF, NYHA III”), the goal of prescribing a drug should be determined (e.g., “improvement of dyspnea and fatigue”). This step is followed by a systematic evaluation of all treatment options, including nonpharmacological options. The options can be compared with regard to their safety (e.g., interactions, contraindications), tolerability (e.g., side effect profile), effectiveness (e.g., maximum expected effect on symptoms), price (e.g., monthly costs), and simplicity (e.g., frequency of dosing regimen). Some of this information can be found in pharmaceutical advertisements (e.g., in the safety warnings box), whereas other information does not need to be included (e.g., price). The patient should be provided with information on the chosen treatment, instructions on the use, and potential safety warnings. Finally, the treatment and its effect should be reevaluated on a regular basis.\\nQuality improvement\", 'image': '143.jpg'}, {'option': 'D\\nMelliFly should not be prescribed because its side effect profile is unfavorable for this patient', 'percent': '8%', 'answer': \"Tolerability (e.g., side effects) should be taken into account when prescribing a drug. Pharmaceutical advertisements typically mention the most important side effects, which should be considered in relation to the patient's medical history and preferences. Poor tolerability may outweigh the benefits of a drug. In this patient, the benefits of treatment with the new drug (overall improved outcome of heart failure) would outweigh the risks and relative frequencies of side effects (e.g., hypoglycemia, urinary tract infections). Furthermore, another aspect of the drug has to be evaluated before considering its tolerability.\", 'image': '143.jpg'}, {'option': \"E\\nMelliFly should be prescribed because it effectively lowers this patient's risk of hospitalization\", 'percent': '30%', 'answer': 'Effectiveness should be taken into account when prescribing a drug to a patient. The risk of hospitalization for heart failure is effectively lowered by the drug in the advertisement and the results of the study are statistically significant (HR = 0.63, p < 0.001). However, another aspect of the drug has to be evaluated before considering its effectiveness for this patient.', 'image': '143.jpg'}], 'correct_answer': \"C\\nMelliFly should not be prescribed because the advertisement does not feature this patient's clinical syndrome\\n48%\\nThis patient has a history of congestive heart failure and an ejection fraction (EF) of 55%, which indicates that he has heart failure with preserved EF. The advertisement states that the medicine is targeted at patients with heart failure with reduced EF (i.e., with an EF of < 40%). The medication does not address this patient's specific condition, so it would not be appropriate to prescribe it.\\n\\nAfter a clear definition of a patient's problem (e.g., “congestive heart failure with preserved EF, NYHA III”), the goal of prescribing a drug should be determined (e.g., “improvement of dyspnea and fatigue”). This step is followed by a systematic evaluation of all treatment options, including nonpharmacological options. The options can be compared with regard to their safety (e.g., interactions, contraindications), tolerability (e.g., side effect profile), effectiveness (e.g., maximum expected effect on symptoms), price (e.g., monthly costs), and simplicity (e.g., frequency of dosing regimen). Some of this information can be found in pharmaceutical advertisements (e.g., in the safety warnings box), whereas other information does not need to be included (e.g., price). The patient should be provided with information on the chosen treatment, instructions on the use, and potential safety warnings. Finally, the treatment and its effect should be reevaluated on a regular basis.\\nQuality improvement\\nGIVE FEEDBACK\", 'tag': 'cardiovascular-medicine, primary-care-adult, geriatrics'}\n",
            "The correct answer is \"C. MelliFly should not be prescribed because the advertisement does not feature this patient's clinical syndrome\". This is because the patient has heart failure with preserved ejection fraction (EF), as indicated by his EF of 55%. The advertisement for MelliFly states that it is intended for patients with heart failure with reduced EF (EF < 40%). Therefore, this medication would not be appropriate for this patient's specific condition.\n",
            "\n",
            "Option A is incorrect because the patient's current medications (hydrochlorothiazide, spironolactone, and metformin) are not mentioned in the safety warnings box of the MelliFly advertisement, suggesting that there are no known interactions between these drugs and MelliFly.\n",
            "\n",
            "Option B is incorrect because while a simple dosing regimen could be beneficial for this patient, who has difficulty remembering his medication regimen, the appropriateness of the medication for the patient's specific condition should be considered first.\n",
            "\n",
            "Option D is incorrect because while the side effect profile of a medication should be considered, the benefits of MelliFly (improved heart failure outcomes) would likely outweigh the risks and relative frequencies of side effects for this patient. However, the medication's appropriateness for the patient's specific condition should be considered first.\n",
            "\n",
            "Option E is incorrect because while MelliFly has been shown to effectively lower the risk of hospitalization for heart failure, the medication's appropriateness for the patient's specific condition (heart failure with preserved EF) should be considered first.\n",
            "<class 'str'>\n",
            "{\"question\": \"A 68-year-old woman with a history of chronic obstructive pulmonary disease (COPD) presents to the clinic with worsening shortness of breath and cough over the past 6 months. She has been using her albuterol inhaler more frequently. She has a 40-pack-year smoking history. Her current medications include albuterol and tiotropium. Her vital signs are within normal limits. Physical examination reveals decreased breath sounds and prolonged expiration. Pulmonary function tests show a decreased FEV1/FVC ratio and decreased diffusing capacity. The physician considers prescribing a new medication, Roflumilast, which she recently read about in a pharmaceutical advertisement. Based on the pharmaceutical advertisement shown, which of the following statements about Roflumilast is most appropriate with regard to this patient?\", \"hint\": \"This patient has COPD with worsening symptoms. When prescribing a medication to a patient, the physician should follow a systematic approach and first consider the patient's individual problem.\", \"options\": [{\"option\": \"A\\nRoflumilast should not be prescribed because of potential drug interactions with this patient's other medications\", \"percent\": \"10%\", \"answer\": \"Safety concerns (e.g., potential interactions) should be taken into account when prescribing a drug. Pharmaceutical advertisements typically feature a safety warnings box that includes information about potential drug interactions and important risks, which should be weighed against the potential benefits of the drug. This patient takes albuterol and tiotropium, none of which is mentioned in the safety warnings box of the advertisement.\", \"image\": \"144.jpg\"}, {\"option\": \"B\\nRoflumilast should be prescribed to this patient because of its simple dosing regimen\", \"percent\": \"10%\", \"answer\": \"The simplicity of a treatment regimen should be taken into account when prescribing a drug. However, another aspect of the drug has to be evaluated before considering the dosing regimen.\", \"image\": \"144.jpg\"}, {\"option\": \"C\\nRoflumilast should not be prescribed because the advertisement does not feature this patient's clinical syndrome\", \"percent\": \"50%\", \"answer\": \"This patient has a history of COPD with worsening symptoms. The advertisement states that the medicine is targeted at patients with severe COPD associated with chronic bronchitis and a history of exacerbations. The medication addresses this patient's specific condition, so it would be appropriate to prescribe it.\", \"image\": \"144.jpg\"}, {\"option\": \"D\\nRoflumilast should not be prescribed because its side effect profile is unfavorable for this patient\", \"percent\": \"10%\", \"answer\": \"Tolerability (e.g., side effects) should be taken into account when prescribing a drug. Pharmaceutical advertisements typically mention the most important side effects, which should be considered in relation to the patient's medical history and preferences. Poor tolerability may outweigh the benefits of a drug. In this patient, the benefits of treatment with the new drug (reduction in exacerbations) would outweigh the risks and relative frequencies of side effects (e.g., diarrhea, weight loss). Furthermore, another aspect of the drug has to be evaluated before considering its tolerability.\", \"image\": \"144.jpg\"}, {\"option\": \"E\\nRoflumilast should be prescribed because it effectively lowers this patient's risk of exacerbations\", \"percent\": \"20%\", \"answer\": \"Effectiveness should be taken into account when prescribing a drug to a patient. The risk of exacerbations in COPD is effectively lowered by the drug in the advertisement and the results of the study are statistically significant. However, another aspect of the drug has to be evaluated before considering its effectiveness for this patient.\", \"image\": \"144.jpg\"}], \"correct_answer\": \"C\\nRoflumilast should be prescribed because the advertisement features this patient's clinical syndrome\\n50%\\nThis patient has a history of COPD with worsening symptoms. The advertisement states that the medicine is targeted at patients with severe COPD associated with chronic bronchitis and a history of exacerbations. The medication addresses this patient's specific condition, so it would be appropriate to prescribe it.\", \"tag\": \"pulmonary-medicine, primary-care-adult, geriatrics\"}\n",
            "Output string has been stored in '/content/drive/My Drive/results/d5-ans/output_143.json.txt'\n",
            "\n",
            "\n",
            "Contents of 27.json:\n",
            "{'question': 'A 6-year-old girl is brought to the physician by her parents because of a 2-month history of intermittent wheezing and nonproductive cough. Her symptoms worsened after she and her family moved to the countryside 1 month ago. The child has a history of atopic dermatitis. Her temperature is 37.1°C (98.8°F), pulse is 95/min, respirations are 29/min, and blood pressure is 90/60 mm Hg. Bilateral scattered wheezes are heard on auscultation of the chest. Pulmonary function testing is most likely to show which of the following sets of findings?\\nFEV1 FVC DLCO Total lung capacity\\nA Decreased normal decreased increased\\nB Decreased decreased normal decreased\\nC Decreased decreased decreased decreased\\nD Normal normal decreased normal\\nE Decreased normal increased increased', 'hint': 'In a patient with a history of atopy, wheezing and nonproductive cough that worsened after probable exposure to allergens (the family moved to the countryside) are suggestive of bronchial asthma (BA).', 'options': [{'option': 'A\\nA', 'percent': '25%', 'answer': 'This set of findings is compatible with emphysema, a form of chronic obstructive pulmonary disease (COPD). Emphysema decreases the surface area available for gaseous exchange, resulting in decreased DLCO. COPD can also manifest with wheezing, an obstructive pattern on pulmonary function tests including decreased FEV1, and, in the case of air trapping, increased total lung capacity with normal or decreased FVC. Although early-onset emphysema can occur in patients with certain rare hereditary disorders (e.g., alpha-1 antitrypsin deficiency), this young girl most likely has bronchial asthma rather than COPD.', 'image': None}, {'option': 'B\\nB', 'percent': '42%', 'answer': 'This set of findings is compatible with restrictive lung disease (RLD) due to extrapulmonary causes (e.g., obesity, neuromuscular disease, thoracic deformities). FEV1, FVC, and total lung capacity (TLC) are decreased but DLCO is typically normal, as the intrinsic quality of the lung is not affected. In RLD due to extrapulmonary causes, the FEV1:FVC ratio is typically normal because FVC and FEV1 decrease in equal proportion.', 'image': None}, {'option': 'C\\nC', 'percent': '6%', 'answer': \"This set of findings is compatible with restrictive lung disease (RLD) caused by intrinsic lung impairment (e.g., interstitial lung disease, pneumonia, pulmonary edema). All lung volumes and capacities, including FEV1, FVC, and total lung capacity, are decreased as a result of the lungs' impaired ability to expand (decreased compliance). In RLD caused by intrinsic lung impairment, the FEV1:FVC ratio is normal or increased because the decrease in FVC is more substantial than the decrease in FEV1. Additionally, DLCO is decreased because the surface area for gaseous exchange is diminished.\", 'image': None}, {'option': 'D\\nD', 'percent': '5%', 'answer': 'This set of findings is compatible with primary pulmonary vascular disease (e.g., pulmonary embolism, idiopathic pulmonary hypertension), severe anemia, and carboxyhemoglobinemia (e.g., in smokers, carbon monoxide poisoning). As these conditions do not cause a restrictive or obstructive pattern, lung volumes and capacities are not affected. These conditions instead decrease lung perfusion, resulting in decreased DLCO.', 'image': None}, {'option': 'E\\nE', 'percent': '22%', 'answer': 'This set of findings is consistent with BA. FEV1 decreases as a result of increased airway resistance (due to airway narrowing). Total lung capacity (TLC) and FVC can be normal but in the case of severe BA, air trapping occurs, resulting in increased residual volume and increased TLC; FVC might also decrease if air trapping is severe. In BA, the diffusion capacity of the lung for carbon monoxide (DLCO) is normal or increased. The increase in DLCO is thought to be due to a combination of increased pulmonary capillary bed recruitment and increases in alveolar pressure and/or surface area (as a result of air trapping and hyperinflation). In BA and other obstructive lung diseases (e.g., chronic obstructive pulmonary disease), the FEV1:FVC ratio is typically decreased because the decrease in FEV1 is more substantial than the decrease in FVC.\\n\\nPulmonary function tests (PFTs), such as spirometry and single-breath diffusion capacity (DLCO measurement), can be performed in children who are able to understand and follow instructions for breathing maneuvers (typically children older than 5 years of age). Spirometry is used to determine the severity of BA and to guide therapy.\\nPulmonary function testing', 'image': None}], 'correct_answer': 'E\\nE\\n22%\\nThis set of findings is consistent with BA. FEV1 decreases as a result of increased airway resistance (due to airway narrowing). Total lung capacity (TLC) and FVC can be normal but in the case of severe BA, air trapping occurs, resulting in increased residual volume and increased TLC; FVC might also decrease if air trapping is severe. In BA, the diffusion capacity of the lung for carbon monoxide (DLCO) is normal or increased. The increase in DLCO is thought to be due to a combination of increased pulmonary capillary bed recruitment and increases in alveolar pressure and/or surface area (as a result of air trapping and hyperinflation). In BA and other obstructive lung diseases (e.g., chronic obstructive pulmonary disease), the FEV1:FVC ratio is typically decreased because the decrease in FEV1 is more substantial than the decrease in FVC.\\n\\nPulmonary function tests (PFTs), such as spirometry and single-breath diffusion capacity (DLCO measurement), can be performed in children who are able to understand and follow instructions for breathing maneuvers (typically children older than 5 years of age). Spirometry is used to determine the severity of BA and to guide therapy.\\nPulmonary function testing\\nGIVE FEEDBACK', 'tag': 'allergy-and-immunology, pulmonary-and-critical-care-medicine, pediatrics'}\n",
            "The correct answer is E. The patient's history of atopy, wheezing, and nonproductive cough that worsened after probable exposure to allergens (the family moved to the countryside) are suggestive of bronchial asthma (BA). In BA, FEV1 decreases due to increased airway resistance from airway narrowing. Total lung capacity (TLC) and FVC can be normal but in severe BA, air trapping occurs, resulting in increased residual volume and increased TLC; FVC might also decrease if air trapping is severe. The diffusion capacity of the lung for carbon monoxide (DLCO) is normal or increased in BA due to a combination of increased pulmonary capillary bed recruitment and increases in alveolar pressure and/or surface area (as a result of air trapping and hyperinflation). \n",
            "\n",
            "Option A is incorrect because it describes findings compatible with emphysema, a form of chronic obstructive pulmonary disease (COPD), which is unlikely in this young girl.\n",
            "\n",
            "Option B and C are incorrect because they describe findings compatible with restrictive lung disease (RLD) due to extrapulmonary causes and intrinsic lung impairment respectively. The patient's symptoms and history do not suggest RLD.\n",
            "\n",
            "Option D is incorrect because it describes findings compatible with primary pulmonary vascular disease, severe anemia, and carboxyhemoglobinemia. These conditions do not cause a restrictive or obstructive pattern, and there is no evidence to suggest these conditions in the patient's history.\n",
            "<class 'str'>\n",
            "{\"question\": \"A 45-year-old man comes to the physician because of a 6-month history of progressive shortness of breath and nonproductive cough. He has a 20-pack-year history of smoking. His temperature is 37.2°C (99.0°F), pulse is 90/min, respirations are 22/min, and blood pressure is 130/80 mm Hg. On physical examination, decreased breath sounds and scattered wheezes are heard on auscultation of the chest. Pulmonary function testing is most likely to show which of the following sets of findings?\\nFEV1 FVC DLCO Total lung capacity\\nA Decreased normal decreased increased\\nB Decreased decreased normal decreased\\nC Decreased decreased decreased decreased\\nD Normal normal decreased normal\\nE Decreased normal increased increased\", \"hint\": \"In a patient with a history of smoking, progressive shortness of breath and nonproductive cough are suggestive of chronic obstructive pulmonary disease (COPD).\", \"options\": [{\"option\": \"A\\nA\", \"percent\": \"45%\", \"answer\": \"This set of findings is compatible with emphysema, a form of chronic obstructive pulmonary disease (COPD). Emphysema decreases the surface area available for gaseous exchange, resulting in decreased DLCO. COPD can also manifest with wheezing, an obstructive pattern on pulmonary function tests including decreased FEV1, and, in the case of air trapping, increased total lung capacity with normal or decreased FVC. Given the patient's history of smoking and symptoms, COPD is the most likely diagnosis.\", \"image\": null}, {\"option\": \"B\\nB\", \"percent\": \"20%\", \"answer\": \"This set of findings is compatible with restrictive lung disease (RLD) due to extrapulmonary causes (e.g., obesity, neuromuscular disease, thoracic deformities). FEV1, FVC, and total lung capacity (TLC) are decreased but DLCO is typically normal, as the intrinsic quality of the lung is not affected. In RLD due to extrapulmonary causes, the FEV1:FVC ratio is typically normal because FVC and FEV1 decrease in equal proportion. However, the patient's history and symptoms do not suggest RLD.\", \"image\": null}, {\"option\": \"C\\nC\", \"percent\": \"10%\", \"answer\": \"This set of findings is compatible with restrictive lung disease (RLD) caused by intrinsic lung impairment (e.g., interstitial lung disease, pneumonia, pulmonary edema). All lung volumes and capacities, including FEV1, FVC, and total lung capacity, are decreased as a result of the lungs' impaired ability to expand (decreased compliance). In RLD caused by intrinsic lung impairment, the FEV1:FVC ratio is normal or increased because the decrease in FVC is more substantial than the decrease in FEV1. Additionally, DLCO is decreased because the surface area for gaseous exchange is diminished. However, the patient's history and symptoms do not suggest RLD.\", \"image\": null}, {\"option\": \"D\\nD\", \"percent\": \"5%\", \"answer\": \"This set of findings is compatible with primary pulmonary vascular disease (e.g., pulmonary embolism, idiopathic pulmonary hypertension), severe anemia, and carboxyhemoglobinemia (e.g., in smokers, carbon monoxide poisoning). As these conditions do not cause a restrictive or obstructive pattern, lung volumes and capacities are not affected. These conditions instead decrease lung perfusion, resulting in decreased DLCO. However, the patient's history and symptoms do not suggest these conditions.\", \"image\": null}, {\"option\": \"E\\nE\", \"percent\": \"20%\", \"answer\": \"This set of findings is consistent with bronchial asthma (BA). FEV1 decreases as a result of increased airway resistance (due to airway narrowing). Total lung capacity (TLC) and FVC can be normal but in the case of severe BA, air trapping occurs, resulting in increased residual volume and increased TLC; FVC might also decrease if air trapping is severe. In BA, the diffusion capacity of the lung for carbon monoxide (DLCO) is normal or increased. The increase in DLCO is thought to be due to a combination of increased pulmonary capillary bed recruitment and increases in alveolar pressure and/or surface area (as a result of air trapping and hyperinflation). However, the patient's history and symptoms do not suggest BA.\", \"image\": null}], \"correct_answer\": \"A\\nA\\n45%\\nThis set of findings is compatible with emphysema, a form of chronic obstructive pulmonary disease (COPD). Emphysema decreases the surface area available for gaseous exchange, resulting in decreased DLCO. COPD can also manifest with wheezing, an obstructive pattern on pulmonary function tests including decreased FEV1, and, in the case of air trapping, increased total lung capacity with normal or decreased FVC. Given the patient's history of smoking and symptoms, COPD is the most likely diagnosis.\", \"tag\": \"pulmonary-and-critical-care-medicine\"}\n",
            "Output string has been stored in '/content/drive/My Drive/results/d5-ans/output_27.json.txt'\n",
            "\n",
            "\n",
            "Contents of 270.json:\n",
            "{'question': 'Twelve hours after undergoing urgent angioplasty via arterial catheterization of the left femoral artery for critical ischemia of the left leg, a 69-year-old woman has a painful mass in the left groin. She has peripheral artery disease, coronary artery disease, hypercholesterolemia, and type 2 diabetes mellitus. She has smoked one pack of cigarettes daily for 34 years. Current medications include enalapril, aspirin, rivaroxaban, simvastatin, metformin, and sitagliptin. Her temperature is 36.7°C (98°F), pulse is 88/min, and blood pressure is 116/72 mm Hg. Examination shows a 4-cm (1.6-in) tender, pulsatile mass in the left groin. The skin over the mass shows mild ecchymosis but no erythema. A loud bruit is heard on auscultation over this area. Examination of the lower extremities shows no peripheral edema or pulse deficit. Sensation is intact. Laboratory studies, including a complete blood count and serum electrolyte concentrations, are within normal limits. Duplex ultrasonography shows an inhomogeneous hypoechoic sac connected to the left common femoral artery, with pulsatile and turbulent bidirectional blood flow between the artery and the sac. The femoral vein does not communicate with the hematoma. Which of the following is the most appropriate next step in management?', 'hint': 'A postinterventional pulsatile groin mass with a bruit on auscultation, together with ultrasound findings of a hypoechoic sac connected to the femoral artery, is in keeping with a femoral artery pseudoaneurysm. The treatment thereof is determined according to the aneurysm size (more or less than 3 cm) and the presence of complications (e.g., hemodynamic instability, limb ischemia, skin necrosis, infection, rapid hematoma expansion).', 'options': [{'option': 'A\\nUltrasound-guided thrombin injection', 'percent': '17%', 'answer': 'Ultrasound-guided thrombin injection into the pseudoaneurysm sac initiates the rapid formation of a fibrin clot, stopping blood flow to the hematoma. This procedure has become the gold standard for the treatment of uncomplicated postcatheterization pseudoaneurysms that measure ≥ 3 cm, and it has a success rate of > 90%. Pseudoaneurysms are most often iatrogenic (e.g., a complication of vascular puncture or cardiovascular surgery) and typically manifest within 24 hours following the procedure. In some cases, iatrogenic pseudoaneurysms only become symptomatic 7–10 days after the intervention. The incidence of iatrogenic pseudoaneurysms is low: they are reported following < 1% of all diagnostic and therapeutic catheterizations.\\n\\nIn contrast, true aneurysms of the femoral artery usually require open surgical repair if they become symptomatic or measure ≥ 3 cm.\\nAneurysm', 'image': None}, {'option': 'B\\nUltrasound-guided compression', 'percent': '19%', 'answer': 'Ultrasound-guided compression (UGC) is the first-line treatment for symptomatic iatrogenic arteriovenous fistulas, an important but extremely rare differential diagnosis for a postinterventional groin mass with a bruit. However, this condition is often initially asymptomatic and manifests 48 hours to several months after the intervention. Additional symptoms typically include fatigue, lower extremity ischemia and/or edema, deep vein thrombosis, varicosis, neuropathy, and high-output cardiac failure. Moreover, duplex ultrasonography would show involvement of the femoral vein and a continuous rather than pulsatile flow. For uncomplicated pseudoaneurysms, UGC is now rarely used because it is not as effective as other procedures.', 'image': None}, {'option': 'C\\nObservation and serial imaging', 'percent': '23%', 'answer': \"Observation and serial imaging are indicated for uncomplicated pseudoaneurysms that measure < 3 cm if they are asymptomatic and have been present for < 6 weeks, as they may resolve spontaneously. Since this patient's pseudoaneurysm is ≥ 3 cm in size and symptomatic, it is likely to continue to grow without intervention and, therefore, requires treatment.\", 'image': None}, {'option': 'D\\nOpen surgical repair', 'percent': '25%', 'answer': 'Open surgical repair is indicated for complicated pseudoaneurysms, i.e., pseudoaneurysms that cause hemodynamic instability or tissue compromise (e.g., limb ischemia, neuropathy, skin necrosis), expand rapidly, or show signs of infection (e.g., erythema, warmth), and for uncomplicated pseudoaneurysms that cannot be repaired through less invasive measures. Because this patient has not yet received any treatment and shows no symptoms that would classify the pseudoaneurysm as complicated, open surgical repair is not appropriate at this time.', 'image': None}, {'option': 'E\\nCovered stent implantation', 'percent': '17%', 'answer': 'Covered stent implantation may be utilized if other noninvasive treatments have not been successful or if a pseudoaneurysm is detected on angiography prior to removal of the catheter during the initial procedure. Alternatively, coil embolization can be considered for endovascular therapy. Because this patient has not yet undergone noninvasive treatment, stent implantation and coil embolization are not indicated at this time.', 'image': None}], 'correct_answer': 'A\\nUltrasound-guided thrombin injection\\n17%\\nUltrasound-guided thrombin injection into the pseudoaneurysm sac initiates the rapid formation of a fibrin clot, stopping blood flow to the hematoma. This procedure has become the gold standard for the treatment of uncomplicated postcatheterization pseudoaneurysms that measure ≥ 3 cm, and it has a success rate of > 90%. Pseudoaneurysms are most often iatrogenic (e.g., a complication of vascular puncture or cardiovascular surgery) and typically manifest within 24 hours following the procedure. In some cases, iatrogenic pseudoaneurysms only become symptomatic 7–10 days after the intervention. The incidence of iatrogenic pseudoaneurysms is low: they are reported following < 1% of all diagnostic and therapeutic catheterizations.\\n\\nIn contrast, true aneurysms of the femoral artery usually require open surgical repair if they become symptomatic or measure ≥ 3 cm.\\nAneurysm\\nGIVE FEEDBACK', 'tag': 'cardiovascular-medicine,hospital-medicine'}\n",
            "The correct answer is \"Ultrasound-guided thrombin injection\" because the patient's presentation and ultrasound findings are consistent with a femoral artery pseudoaneurysm, which is a common complication of femoral artery catheterization. This condition is characterized by a pulsatile groin mass with a bruit on auscultation and a hypoechoic sac connected to the femoral artery on ultrasound. The treatment of choice for uncomplicated pseudoaneurysms that are ≥3 cm, like in this patient, is ultrasound-guided thrombin injection. This procedure involves injecting thrombin into the pseudoaneurysm sac to initiate the rapid formation of a fibrin clot, thereby stopping blood flow to the hematoma.\n",
            "\n",
            "The other options are incorrect for the following reasons:\n",
            "\n",
            "- \"Ultrasound-guided compression\" is the first-line treatment for symptomatic iatrogenic arteriovenous fistulas, not pseudoaneurysms. This condition would also involve the femoral vein and show a continuous flow on ultrasound, which is not the case in this patient.\n",
            "- \"Observation and serial imaging\" is indicated for uncomplicated pseudoaneurysms that are <3 cm, asymptomatic, and have been present for <6 weeks. This patient's pseudoaneurysm is ≥3 cm and symptomatic, so it requires treatment.\n",
            "- \"Open surgical repair\" is indicated for complicated pseudoaneurysms that cause hemodynamic instability or tissue compromise, expand rapidly, or show signs of infection. This patient's pseudoaneurysm is uncomplicated and does not require surgical intervention at this time.\n",
            "- \"Covered stent implantation\" may be utilized if other noninvasive treatments have not been successful or if a pseudoaneurysm is detected on angiography prior to removal of the catheter during the initial procedure. This patient has not yet undergone noninvasive treatment, so stent implantation is not indicated at this time.\n",
            "<class 'str'>\n",
            "{\"question\": \"A 72-year-old man presents to the emergency department with severe pain in his right groin that started suddenly 6 hours ago. He has a history of peripheral artery disease and underwent angioplasty via arterial catheterization of the right femoral artery 2 days ago. He also has hypertension and type 2 diabetes mellitus. His current medications include lisinopril, aspirin, apixaban, atorvastatin, metformin, and glipizide. His temperature is 36.9\\u00b0C (98.4\\u00b0F), pulse is 90/min, and blood pressure is 120/80 mm Hg. Examination shows a 3.5-cm (1.4-in) tender, pulsatile mass in the right groin. The skin over the mass shows mild ecchymosis but no erythema. A loud bruit is heard on auscultation over this area. Examination of the lower extremities shows no peripheral edema or pulse deficit. Sensation is intact. Laboratory studies, including a complete blood count and serum electrolyte concentrations, are within normal limits. Duplex ultrasonography shows an inhomogeneous hypoechoic sac connected to the right common femoral artery, with pulsatile and turbulent bidirectional blood flow between the artery and the sac. The femoral vein does not communicate with the hematoma. Which of the following is the most appropriate next step in management?\", \"hint\": \"A postinterventional pulsatile groin mass with a bruit on auscultation, together with ultrasound findings of a hypoechoic sac connected to the femoral artery, is in keeping with a femoral artery pseudoaneurysm. The treatment thereof is determined according to the aneurysm size (more or less than 3 cm) and the presence of complications (e.g., hemodynamic instability, limb ischemia, skin necrosis, infection, rapid hematoma expansion).\", \"options\": [{\"option\": \"A\\nUltrasound-guided thrombin injection\", \"percent\": \"20%\", \"answer\": \"Ultrasound-guided thrombin injection into the pseudoaneurysm sac initiates the rapid formation of a fibrin clot, stopping blood flow to the hematoma. This procedure has become the gold standard for the treatment of uncomplicated postcatheterization pseudoaneurysms that measure \\u2265 3 cm, and it has a success rate of > 90%. Pseudoaneurysms are most often iatrogenic (e.g., a complication of vascular puncture or cardiovascular surgery) and typically manifest within 24 hours following the procedure. In some cases, iatrogenic pseudoaneurysms only become symptomatic 7\\u201310 days after the intervention. The incidence of iatrogenic pseudoaneurysms is low: they are reported following < 1% of all diagnostic and therapeutic catheterizations.\\n\\nIn contrast, true aneurysms of the femoral artery usually require open surgical repair if they become symptomatic or measure \\u2265 3 cm.\\nAneurysm\", \"image\": null}, {\"option\": \"B\\nUltrasound-guided compression\", \"percent\": \"20%\", \"answer\": \"Ultrasound-guided compression (UGC) is the first-line treatment for symptomatic iatrogenic arteriovenous fistulas, an important but extremely rare differential diagnosis for a postinterventional groin mass with a bruit. However, this condition is often initially asymptomatic and manifests 48 hours to several months after the intervention. Additional symptoms typically include fatigue, lower extremity ischemia and/or edema, deep vein thrombosis, varicosis, neuropathy, and high-output cardiac failure. Moreover, duplex ultrasonography would show involvement of the femoral vein and a continuous rather than pulsatile flow. For uncomplicated pseudoaneurysms, UGC is now rarely used because it is not as effective as other procedures.\", \"image\": null}, {\"option\": \"C\\nObservation and serial imaging\", \"percent\": \"20%\", \"answer\": \"Observation and serial imaging are indicated for uncomplicated pseudoaneurysms that measure < 3 cm if they are asymptomatic and have been present for < 6 weeks, as they may resolve spontaneously. Since this patient's pseudoaneurysm is \\u2265 3 cm in size and symptomatic, it is likely to continue to grow without intervention and, therefore, requires treatment.\", \"image\": null}, {\"option\": \"D\\nOpen surgical repair\", \"percent\": \"20%\", \"answer\": \"Open surgical repair is indicated for complicated pseudoaneurysms, i.e., pseudoaneurysms that cause hemodynamic instability or tissue compromise (e.g., limb ischemia, neuropathy, skin necrosis), expand rapidly, or show signs of infection (e.g., erythema, warmth), and for uncomplicated pseudoaneurysms that cannot be repaired through less invasive measures. Because this patient has not yet received any treatment and shows no symptoms that would classify the pseudoaneurysm as complicated, open surgical repair is not appropriate at this time.\", \"image\": null}, {\"option\": \"E\\nCovered stent implantation\", \"percent\": \"20%\", \"answer\": \"Covered stent implantation may be utilized if other noninvasive treatments have not been successful or if a pseudoaneurysm is detected on angiography prior to removal of the catheter during the initial procedure. Alternatively, coil embolization can be considered for endovascular therapy. Because this patient has not yet undergone noninvasive treatment, stent implantation and coil embolization are not indicated at this time.\", \"image\": null}], \"correct_answer\": \"A\\nUltrasound-guided thrombin injection\\n20%\\nUltrasound-guided thrombin injection into the pseudoaneurysm sac initiates the rapid formation of a fibrin clot, stopping blood flow to the hematoma. This procedure has become the gold standard for the treatment of uncomplicated postcatheterization pseudoaneurysms that measure \\u2265 3 cm, and it has a success rate of > 90%. Pseudoaneurysms are most often iatrogenic (e.g., a complication of vascular puncture or cardiovascular surgery) and typically manifest within 24 hours following the procedure. In some cases, iatrogenic pseudoaneurysms only become symptomatic 7\\u201310 days after the intervention. The incidence of iatrogenic pseudoaneurysms is low: they are reported following < 1% of all diagnostic and therapeutic catheterizations.\\n\\nIn contrast, true aneurysms of the femoral artery usually require open surgical repair if they become symptomatic or measure \\u2265 3 cm.\\nAneurysm\\nGIVE FEEDBACK\", \"tag\": \"cardiovascular-medicine,hospital-medicine\"}\n",
            "Output string has been stored in '/content/drive/My Drive/results/d5-ans/output_270.json.txt'\n",
            "\n",
            "\n",
            "Contents of 40.json:\n",
            "{'question': 'A 72-year-old woman comes to the physician because of a 1-month history of progressive fatigue and shortness of breath. Physical examination shows generalized pallor. Laboratory studies show:\\nHemoglobin 5.8 g/dL\\nHematocrit 17%\\nMean corpuscular volume 86 μm3\\nLeukocyte count 6200/mm3 with a normal differential\\nPlatelet count 240,000/mm3\\nA bone marrow aspirate shows an absence of erythroid precursor cells. This patient’s condition is most likely associated with which of the following?', 'hint': 'Anemia with an absence of RBC precursors but normal production of platelets and WBCs indicates pure red cell aplasia (PRCA).', 'options': [{'option': 'A\\nCold agglutinins', 'percent': '23%', 'answer': 'Cold agglutinins can cause autoimmune hemolytic anemia, which manifests with normocytic anemia. However, unlike this patient, erythroid precursor cells would be present.', 'image': None}, {'option': 'B\\nFANCA mutation', 'percent': '30%', 'answer': 'FANCA mutation is associated with Fanconi anemia, which typically manifests in childhood with pancytopenia (rather than pure red cell aplasia), developmental delay, skeletal, and organ abnormalities (e.g., short stature, thumb and forearm malformations, café-au-lait spots, and microcephaly). Furthermore, almost 50% of patients develop acute myeloid leukemia or myelodysplastic syndrome in early adulthood.', 'image': None}, {'option': 'C\\nHbF persistence', 'percent': '4%', 'answer': 'HbF persistence with pure red cell aplasia is typically found in Diamond-Blackfan anemia. Unlike this patient, Diamond-Blackfan anemia typically manifests in childhood with macrocytic, nonmegaloblastic anemia, and congenital malformations (e.g., short stature, webbed neck, low set ears, small jaw, and triphalangeal thumbs).', 'image': None}, {'option': 'D\\nThymic tumor', 'percent': '18%', 'answer': 'PRCA in adults is most often idiopathic but can be associated with other conditions. Thymoma, a thymic tumor, may cause a paraneoplastic syndrome that manifests with PRCA. Although the pathophysiology of PRCA is not well understood, it is thought to be related to abnormal T-cell function and IgG antibodies that target erythroblasts and erythropoietin. PRCA may also be associated with myelodysplastic syndrome, drugs (e.g., phenytoin, chloramphenicol), and parvovirus B19 infection.\\n\\nTreatment of pure red cell aplasia in this patient would include a thymectomy, RBC transfusions, and additional medications such as corticosteroids, cyclosporine, or cyclophosphamide if surgery alone does not lead to remission of the aplasia.\\nAnemia', 'image': None}, {'option': 'E\\nLead poisoning', 'percent': '24%', 'answer': 'Lead poisoning typically manifests with microcytic, hypochromic anemia as well as abdominal pain (lead colic), Burton line, and/or paralysis of the radial or peroneal nerve (wrist drop/foot drop). This patient has a normal MCV and lacks the other typical features of lead poisoning.', 'image': None}], 'correct_answer': 'D\\nThymic tumor\\n18%\\nPRCA in adults is most often idiopathic but can be associated with other conditions. Thymoma, a thymic tumor, may cause a paraneoplastic syndrome that manifests with PRCA. Although the pathophysiology of PRCA is not well understood, it is thought to be related to abnormal T-cell function and IgG antibodies that target erythroblasts and erythropoietin. PRCA may also be associated with myelodysplastic syndrome, drugs (e.g., phenytoin, chloramphenicol), and parvovirus B19 infection.\\n\\nTreatment of pure red cell aplasia in this patient would include a thymectomy, RBC transfusions, and additional medications such as corticosteroids, cyclosporine, or cyclophosphamide if surgery alone does not lead to remission of the aplasia.\\nAnemia\\nGIVE FEEDBACK', 'tag': 'hematology, primary-care-adult, family-medicine-and-general-practice'}\n",
            "The correct answer is \"D. Thymic tumor\" because the patient's condition, characterized by anemia with an absence of red blood cell (RBC) precursors but normal production of platelets and white blood cells (WBCs), indicates pure red cell aplasia (PRCA). PRCA in adults is often idiopathic but can be associated with other conditions such as thymoma, a thymic tumor. Thymoma may cause a paraneoplastic syndrome that manifests with PRCA. The pathophysiology of PRCA is thought to be related to abnormal T-cell function and IgG antibodies that target erythroblasts and erythropoietin. \n",
            "\n",
            "The other options are incorrect for the following reasons:\n",
            "\n",
            "A. Cold agglutinins: Cold agglutinins can cause autoimmune hemolytic anemia, which manifests with normocytic anemia. However, unlike this patient, erythroid precursor cells would be present.\n",
            "\n",
            "B. FANCA mutation: FANCA mutation is associated with Fanconi anemia, which typically manifests in childhood with pancytopenia (rather than pure red cell aplasia), developmental delay, skeletal, and organ abnormalities. Furthermore, almost 50% of patients develop acute myeloid leukemia or myelodysplastic syndrome in early adulthood.\n",
            "\n",
            "C. HbF persistence: HbF persistence with pure red cell aplasia is typically found in Diamond-Blackfan anemia. Unlike this patient, Diamond-Blackfan anemia typically manifests in childhood with macrocytic, nonmegaloblastic anemia, and congenital malformations.\n",
            "\n",
            "E. Lead poisoning: Lead poisoning typically manifests with microcytic, hypochromic anemia as well as abdominal pain (lead colic), Burton line, and/or paralysis of the radial or peroneal nerve (wrist drop/foot drop). This patient has a normal MCV and lacks the other typical features of lead poisoning.\n",
            "<class 'str'>\n",
            "{\"question\": \"A 65-year-old man presents to the clinic with a 2-month history of fatigue and shortness of breath. Physical examination reveals pallor and splenomegaly. Laboratory studies show:\\nHemoglobin 6.2 g/dL\\nHematocrit 18%\\nMean corpuscular volume 88 \\u03bcm3\\nLeukocyte count 7000/mm3 with a normal differential\\nPlatelet count 250,000/mm3\\nA bone marrow biopsy shows hypercellularity with increased megakaryocytes. This patient's condition is most likely associated with which of the following?\", \"hint\": \"The patient's presentation of anemia, splenomegaly, and increased megakaryocytes in the bone marrow is suggestive of myelofibrosis.\", \"options\": [{\"option\": \"A\\nB12 deficiency\", \"percent\": \"20%\", \"answer\": \"B12 deficiency typically presents with macrocytic anemia, neurological symptoms, and hypersegmented neutrophils on peripheral smear. This patient's normal MCV and lack of neurological symptoms make this unlikely.\", \"image\": null}, {\"option\": \"B\\nIron deficiency\", \"percent\": \"25%\", \"answer\": \"Iron deficiency anemia typically presents with microcytic, hypochromic anemia and symptoms of iron deficiency such as pica or restless leg syndrome. This patient's normal MCV and lack of these symptoms make this unlikely.\", \"image\": null}, {\"option\": \"C\\nJAK2 mutation\", \"percent\": \"30%\", \"answer\": \"JAK2 mutation is associated with myeloproliferative disorders, including myelofibrosis. This patient's presentation of anemia, splenomegaly, and increased megakaryocytes in the bone marrow is suggestive of myelofibrosis.\", \"image\": null}, {\"option\": \"D\\nThalassemia\", \"percent\": \"15%\", \"answer\": \"Thalassemia typically presents with microcytic, hypochromic anemia and target cells on peripheral smear. This patient's normal MCV and lack of target cells make this unlikely.\", \"image\": null}, {\"option\": \"E\\nLead poisoning\", \"percent\": \"10%\", \"answer\": \"Lead poisoning typically presents with microcytic, hypochromic anemia, abdominal pain, and neurologic symptoms. This patient's normal MCV and lack of these symptoms make this unlikely.\", \"image\": null}], \"correct_answer\": \"C\\nJAK2 mutation\\n30%\\nJAK2 mutation is associated with myeloproliferative disorders, including myelofibrosis. This patient's presentation of anemia, splenomegaly, and increased megakaryocytes in the bone marrow is suggestive of myelofibrosis.\", \"tag\": \"hematology, primary-care-adult, family-medicine-and-general-practice\"}\n",
            "\n",
            "The correct answer is \"C. JAK2 mutation\" because the patient's presentation of anemia, splenomegaly, and increased megakaryocytes in the bone marrow is suggestive of myelofibrosis, a myeloproliferative disorder associated with JAK2 mutation.\n",
            "\n",
            "The other options are incorrect for the following reasons:\n",
            "\n",
            "A. B12 deficiency: B12 deficiency typically presents with macrocytic anemia, neurological symptoms, and hypersegmented neutrophils on peripheral smear. This patient's normal MCV and lack of neurological symptoms make this unlikely.\n",
            "\n",
            "B. Iron deficiency: Iron deficiency anemia typically presents with microcytic, hypochromic anemia and symptoms of iron deficiency such as pica or restless leg syndrome. This patient's normal MCV and lack of these symptoms make this unlikely.\n",
            "\n",
            "D. Thalassemia: Thalassemia typically presents with microcytic, hypochromic anemia and target cells on peripheral smear. This patient's normal MCV and lack of target cells make this unlikely.\n",
            "\n",
            "E. Lead poisoning: Lead poisoning typically presents with microcytic, hypochromic anemia, abdominal pain, and neurologic symptoms. This patient's normal MCV and lack of these symptoms make this unlikely.\n",
            "Output string has been stored in '/content/drive/My Drive/results/d5-ans/output_40.json.txt'\n",
            "\n",
            "\n",
            "Contents of 84.json:\n",
            "{'question': 'A 56-year-old man comes to the physician because of chest pain and shortness of breath for 3 days. The pain is present at rest and worsens with deep inspiration. His temperature is 37.2°C (99.0°F), pulse is 102/min, respirations are 23/min, and blood pressure is 135/88 mm Hg. Examination shows decreased breath sounds at the left lower lobe. Laboratory studies show:\\nHematocrit 42%\\nLeukocyte count 6500/μL\\nSerum\\nFasting glucose 90 mg/dL\\nLactate dehydrogenase 165 U/L\\nTotal protein 7.2 g/dL\\nAn x-ray of the chest shows a small left-sided pleural effusion but no other abnormalities. A diagnostic thoracentesis is performed and 100 mL of bloody fluid are aspirated from the left pleural space. Pleural fluid analysis shows a lactate dehydrogenase of 150 U/L, a total protein of 5.1 g/dL, and a glucose concentration of 85 mg/dL. Pleural fluid cytology shows normal cell morphology. Further evaluation of this patient is most likely to show a history of which of the following?', 'hint': 'The serum and pleural fluid analysis fulfills all three Light criteria for exudative pleural effusion: pleural fluid protein:serum protein ratio is greater than 0.5, pleural fluid lactate dehydrogenase (LDH):serum LDH is greater than 0.6, and pleural LDH is more than two-thirds of the upper limit of normal serum LDH (200 U/L).', 'options': [{'option': 'A\\nOropharyngeal dysphagia', 'percent': '13%', 'answer': 'Oropharyngeal dysphagia is a risk factor for aspiration pneumonia, which can cause chest pain, dyspnea, and unilateral exudative pleural effusion (parapneumonic effusion). However, pleural effusion in cases of aspiration pneumonia would be cloudy or purulent rather than bloody.', 'image': None}, {'option': 'B\\nInfliximab use', 'percent': '9%', 'answer': 'Immunosuppression with infliximab is a risk factor for pneumonia, as well as other pulmonary infections including tuberculosis. All of these infections can cause pleuritic chest pain, dyspnea, and an exudative pleural effusion, but would be unlikely to manifest without any lung field abnormalities on x-ray. Furthermore, this patient is afebrile, making an infectious etiology of his symptoms less likely.', 'image': None}, {'option': 'C\\nProlonged immobilization', 'percent': '24%', 'answer': \"This patient's unremarkable chest x-ray findings (no evidence of malignancy or infection) in conjunction with a unilateral, bloody, exudative pleural effusion with normal glucose values and negative cytology make pulmonary embolism (PE) the most likely underlying etiology of this patient's pleural effusion. Prolonged immobilization is an important risk factor that is a component of the pretest probability for PE (Wells score). In PE, the embolic occlusion of a vessel may lead to increased vessel permeability in the downstream pulmonary vessels, causing pleural effusion. Pleural effusion in PE is typically exudative (80% of cases) and may be hemorrhagic, especially if PE is complicated by pulmonary infarction. While chest x-rays are often normal in patients with PE, features that suggest PE include an enlarged pulmonary artery (Fleischner sign), hyperlucent lung tissue distal to the obstruction (Westermark sign), and a wedge-shaped opacity in the periphery of the lung (Hampton hump).\\n\\nDiagnosis is confirmed with CT pulmonary angiography showing a filling defect of the pulmonary arteries, or with ventilation/perfusion scintigraphy.\\nPleural effusion\", 'image': None}, {'option': 'D\\nCongestive heart failure', 'percent': '21%', 'answer': 'Left ventricular dysfunction associated with congestive heart failure can lead to dyspnea, pulmonary edema, and pleural effusions due to increased hydrostatic pressure in the pulmonary vasculature. However, these effusions are transudates and typically occur bilaterally. A hemorrhagic, unilateral exudate would not be expected.', 'image': None}, {'option': 'E\\nAsbestos exposure', 'percent': '26%', 'answer': 'Asbestos exposure is a risk factor for asbestosis and lung malignancies (e.g., lung cancer and mesothelioma), which can also manifest with chest pain, dyspnea, and a bloody, exudative pleural effusion. However, pleural thickening or pleural plaques would be expected on chest x-ray in asbestosis. In addition, cytology showed no evidence of malignancy, and the patient does not present with any symptoms of a malignant disease (e.g., chronic cough, weight loss, hemoptysis).', 'image': None}, {'option': 'F\\nAlcoholic cirrhosis', 'percent': '7%', 'answer': 'Alcoholic cirrhosis can lead to a transudative pleural effusion due to hypoproteinemia and/or hypoalbuminemia. The decreased hepatic production of serum proteins decreases oncotic pressure, which can lead to bilateral transudative pleural effusion. However, a hemorrhagic, unilateral exudate would not be expected.', 'image': None}], 'correct_answer': \"C\\nProlonged immobilization\\n24%\\nThis patient's unremarkable chest x-ray findings (no evidence of malignancy or infection) in conjunction with a unilateral, bloody, exudative pleural effusion with normal glucose values and negative cytology make pulmonary embolism (PE) the most likely underlying etiology of this patient's pleural effusion. Prolonged immobilization is an important risk factor that is a component of the pretest probability for PE (Wells score). In PE, the embolic occlusion of a vessel may lead to increased vessel permeability in the downstream pulmonary vessels, causing pleural effusion. Pleural effusion in PE is typically exudative (80% of cases) and may be hemorrhagic, especially if PE is complicated by pulmonary infarction. While chest x-rays are often normal in patients with PE, features that suggest PE include an enlarged pulmonary artery (Fleischner sign), hyperlucent lung tissue distal to the obstruction (Westermark sign), and a wedge-shaped opacity in the periphery of the lung (Hampton hump).\\n\\nDiagnosis is confirmed with CT pulmonary angiography showing a filling defect of the pulmonary arteries, or with ventilation/perfusion scintigraphy.\\nPleural effusion\\nGIVE FEEDBACK\", 'tag': 'cardiovascular-medicine,pulmonary-and-critical-care-medicine,emergency-medicine-adult-and-pediatric'}\n",
            "The correct answer is \"Prolonged immobilization\" because the patient's symptoms and test results are consistent with a pulmonary embolism (PE). Prolonged immobilization is a known risk factor for PE. In PE, an embolus blocks a pulmonary vessel, leading to increased vessel permeability downstream and causing a pleural effusion. The effusion in PE is typically exudative and may be bloody, especially if complicated by pulmonary infarction. The patient's chest x-ray is unremarkable, which is often the case in PE. \n",
            "\n",
            "The other options are incorrect for the following reasons:\n",
            "\n",
            "- \"Oropharyngeal dysphagia\" is a risk factor for aspiration pneumonia, which can cause similar symptoms and a unilateral exudative pleural effusion. However, the effusion in aspiration pneumonia would be cloudy or purulent, not bloody.\n",
            "\n",
            "- \"Infliximab use\" can lead to pneumonia and other pulmonary infections, which can cause similar symptoms and an exudative pleural effusion. However, these conditions would likely show lung field abnormalities on x-ray, which this patient does not have.\n",
            "\n",
            "- \"Congestive heart failure\" can cause dyspnea, pulmonary edema, and pleural effusions due to increased hydrostatic pressure in the pulmonary vasculature. However, these effusions are typically bilateral and transudative, not unilateral and exudative.\n",
            "\n",
            "- \"Asbestos exposure\" is a risk factor for asbestosis and lung malignancies, which can cause similar symptoms and a bloody, exudative pleural effusion. However, asbestosis would likely show pleural thickening or plaques on x-ray, which this patient does not have.\n",
            "\n",
            "- \"Alcoholic cirrhosis\" can lead to a transudative pleural effusion due to hypoproteinemia and/or hypoalbuminemia. However, this would typically cause a bilateral transudative effusion, not a unilateral exudative effusion.\n",
            "<class 'str'>\n",
            "{\"question\": \"A 68-year-old woman presents to the emergency department with sudden onset of severe chest pain and shortness of breath. The pain is sharp, located in the center of her chest, and worsens with deep inspiration. Her temperature is 36.8°C (98.2°F), pulse is 110/min, respirations are 22/min, and blood pressure is 130/85 mm Hg. Examination shows decreased breath sounds at the right lower lobe. Laboratory studies show:\\nHematocrit 40%\\nLeukocyte count 7000/μL\\nSerum\\nFasting glucose 95 mg/dL\\nLactate dehydrogenase 170 U/L\\nTotal protein 7.0 g/dL\\nAn x-ray of the chest shows a small right-sided pleural effusion but no other abnormalities. A diagnostic thoracentesis is performed and 120 mL of bloody fluid are aspirated from the right pleural space. Pleural fluid analysis shows a lactate dehydrogenase of 160 U/L, a total protein of 5.0 g/dL, and a glucose concentration of 90 mg/dL. Pleural fluid cytology shows normal cell morphology. Further evaluation of this patient is most likely to show a history of which of the following?\", \"hint\": \"The serum and pleural fluid analysis fulfills all three Light criteria for exudative pleural effusion: pleural fluid protein:serum protein ratio is greater than 0.5, pleural fluid lactate dehydrogenase (LDH):serum LDH is greater than 0.6, and pleural LDH is more than two-thirds of the upper limit of normal serum LDH (200 U/L).\", \"options\": [{\"option\": \"A\\nChronic obstructive pulmonary disease\", \"percent\": \"15%\", \"answer\": \"Chronic obstructive pulmonary disease (COPD) can lead to dyspnea and pleural effusions due to increased hydrostatic pressure in the pulmonary vasculature. However, these effusions are typically transudates and occur bilaterally. A hemorrhagic, unilateral exudate would not be expected.\", \"image\": null}, {\"option\": \"B\\nRecent surgery\", \"percent\": \"25%\", \"answer\": \"Recent surgery, especially orthopedic surgery or any surgery requiring prolonged immobilization, is a known risk factor for pulmonary embolism (PE). In PE, an embolic occlusion of a vessel may lead to increased vessel permeability in the downstream pulmonary vessels, causing pleural effusion. Pleural effusion in PE is typically exudative (80% of cases) and may be hemorrhagic, especially if PE is complicated by pulmonary infarction. While chest x-rays are often normal in patients with PE, features that suggest PE include an enlarged pulmonary artery (Fleischner sign), hyperlucent lung tissue distal to the obstruction (Westermark sign), and a wedge-shaped opacity in the periphery of the lung (Hampton hump).\", \"image\": null}, {\"option\": \"C\\nSystemic lupus erythematosus\", \"percent\": \"20%\", \"answer\": \"Systemic lupus erythematosus (SLE) can cause pleuritis and pleural effusion, but these are typically bilateral and not associated with bloody effusion. In addition, this patient does not have any other symptoms suggestive of SLE.\", \"image\": null}, {\"option\": \"D\\nTuberculosis\", \"percent\": \"15%\", \"answer\": \"Tuberculosis can cause pleuritic chest pain, dyspnea, and an exudative pleural effusion, but would be unlikely to manifest without any lung field abnormalities on x-ray. Furthermore, this patient is afebrile, making an infectious etiology of her symptoms less likely.\", \"image\": null}, {\"option\": \"E\\nSmoking\", \"percent\": \"25%\", \"answer\": \"Smoking is a risk factor for lung cancer, which can also manifest with chest pain, dyspnea, and a bloody, exudative pleural effusion. However, pleural thickening or a mass would be expected on chest x-ray in lung cancer. In addition, cytology showed no evidence of malignancy, and the patient does not present with any symptoms of a malignant disease (e.g., chronic cough, weight loss, hemoptysis).\", \"image\": null}], \"correct_answer\": \"B\\nRecent surgery\\n25%\\nRecent surgery, especially orthopedic surgery or any surgery requiring prolonged immobilization, is a known risk factor for pulmonary embolism (PE). In PE, an embolic occlusion of a vessel may lead to increased vessel permeability in the downstream pulmonary vessels, causing pleural effusion. Pleural effusion in PE is typically exudative (80% of cases) and may be hemorrhagic, especially if PE is complicated by pulmonary infarction. While chest x-rays are often normal in patients with PE, features that suggest PE include an enlarged pulmonary artery (Fleischner sign), hyperlucent lung tissue distal to the obstruction (Westermark sign), and a wedge-shaped opacity in the periphery of the lung (Hampton hump).\\n\\nDiagnosis is confirmed with CT pulmonary angiography showing a filling defect of the pulmonary arteries, or with ventilation/perfusion scintigraphy.\\nPleural effusion\\nGIVE FEEDBACK\", \"tag\": \"cardiovascular-medicine,pulmonary-and-critical-care-medicine,emergency-medicine-adult-and-pediatric\"}\n",
            "Output string has been stored in '/content/drive/My Drive/results/d5-ans/output_84.json.txt'\n",
            "\n",
            "\n",
            "Contents of 33.json:\n",
            "{'question': 'The patient is admitted to the hospital. A stereotactic brain biopsy of the suspicious lesion is performed and shows many large lymphocytes with irregular nuclei. Ophthalmological examination including fundoscopy and slit lamp examination discloses no evidence of intraocular lesions. A contrast-enhanced CT scan of the thorax, abdomen, and pelvis and a bone marrow biopsy show no abnormalities. Which of the following is the most appropriate next step in management?', 'hint': 'This patient has primary CNS lymphoma (PCNSL).', 'options': [{'option': 'A\\nGanciclovir therapy', 'percent': '15%', 'answer': 'Ganciclovir is used to treat cytomegalovirus (CMV) encephalitis, which can cause neurological deficits and cognitive dysfunction and most commonly affects immunocompromised patients. However, CMV encephalitis is usually seen in patients with a CD4+ cell count < 50/mm3, and causes periventricular white matter lesions that are diffusely contrast-enhancing rather than a solitary ring-enhancing lesion. Epstein-Barr virus (EBV) rather than CMV is implicated in the pathogenesis of PCNSL and there are no approved antivirals that specifically target EBV.', 'image': None}, {'option': 'B\\nInterferon-alpha therapy', 'percent': '12%', 'answer': 'Interferon-alpha is used to treat AIDS-related Kaposi sarcoma, hairy cell leukemia, cutaneous T-cell lymphoma, and certain aggressive cases of follicular non-Hodgkin lymphoma but is not used to treat PCNSL.', 'image': None}, {'option': 'C\\nPyrimethamine and sulfadiazine therapy', 'percent': '4%', 'answer': 'A combination of pyrimethamine and sulfadiazine is the treatment of choice in patients with cerebral toxoplasmosis, not PCNSL.', 'image': None}, {'option': 'D\\nMethotrexate therapy', 'percent': '22%', 'answer': 'Combination chemotherapy using a regimen with high-dose methotrexate is the treatment of choice in patients with confirmed PCNSL. Systemic glucocorticoids rapidly decrease the size of a PCNSL and can alleviate tumor-related symptoms but should only be started after a brain biopsy has been obtained. Radiotherapy is indicated if the patient has a poor functional status (i.e., not a candidate for chemotherapy) and for patients with intraorbital or spinal cord lesions. Surgical resection is not typically a part of the management of the PCNSL. In patients with HIV-related PCNSL, administering antiretroviral therapy concurrently with definitive cancer treatment is essential for facilitating immune reconstitution.\\nHIV-associated conditions', 'image': None}, {'option': 'E\\nSurgical resection', 'percent': '47%', 'answer': 'Most PCNSLs are multifocal, deep-seated tumors that do not have a distinct capsule. Surgical resection carries the risk of causing neurological deficits and tumor seeding in other parts of the brain for most PCNSLs. In addition, most studies show no survival benefit in patients who undergo surgical resection of PCNSL as sole therapy.', 'image': None}], 'correct_answer': 'D\\nMethotrexate therapy\\n22%\\nCombination chemotherapy using a regimen with high-dose methotrexate is the treatment of choice in patients with confirmed PCNSL. Systemic glucocorticoids rapidly decrease the size of a PCNSL and can alleviate tumor-related symptoms but should only be started after a brain biopsy has been obtained. Radiotherapy is indicated if the patient has a poor functional status (i.e., not a candidate for chemotherapy) and for patients with intraorbital or spinal cord lesions. Surgical resection is not typically a part of the management of the PCNSL. In patients with HIV-related PCNSL, administering antiretroviral therapy concurrently with definitive cancer treatment is essential for facilitating immune reconstitution.\\nHIV-associated conditions\\nGIVE FEEDBACK', 'tag': 'oncology,neurology,hospital-medicine'}\n",
            "The correct answer is \"Methotrexate therapy\" because the patient's presentation and biopsy results are consistent with primary CNS lymphoma (PCNSL), a rare non-Hodgkin lymphoma confined to the brain, spinal cord, or eye. High-dose methotrexate-based chemotherapy is the first-line treatment for PCNSL. \n",
            "\n",
            "The other options are incorrect for the following reasons:\n",
            "\n",
            "- \"Ganciclovir therapy\" is used to treat cytomegalovirus (CMV) encephalitis, which typically presents with periventricular white matter lesions in immunocompromised patients, not a solitary ring-enhancing lesion as seen in PCNSL. \n",
            "\n",
            "- \"Interferon-alpha therapy\" is used for conditions like AIDS-related Kaposi sarcoma, hairy cell leukemia, cutaneous T-cell lymphoma, and certain aggressive cases of follicular non-Hodgkin lymphoma, but not PCNSL.\n",
            "\n",
            "- \"Pyrimethamine and sulfadiazine therapy\" is the treatment of choice for cerebral toxoplasmosis, not PCNSL.\n",
            "\n",
            "- \"Surgical resection\" is not typically part of the management of PCNSL because these tumors are often multifocal and deep-seated without a distinct capsule. Surgical resection carries the risk of causing neurological deficits and tumor seeding in other parts of the brain. Most studies show no survival benefit in patients who undergo surgical resection of PCNSL as sole therapy.\n",
            "<class 'str'>\n",
            "{\"question\": \"A 45-year-old woman presents with a 2-month history of progressive weakness and numbness in her lower extremities. She also reports urinary incontinence. On examination, she has decreased sensation to light touch and pinprick in the lower extremities, and her reflexes are brisk. An MRI of the spine shows an intramedullary lesion at the level of T10. A biopsy of the lesion shows small round blue cells. Which of the following is the most appropriate next step in management?\", \"hint\": \"This patient has an intramedullary spinal cord tumor, likely an ependymoma.\", \"options\": [{\"option\": \"A\\nHigh-dose corticosteroids\", \"percent\": \"15%\", \"answer\": \"High-dose corticosteroids can be used to reduce edema and inflammation in the spinal cord, but they are not the definitive treatment for an intramedullary spinal cord tumor.\"}, {\"option\": \"B\\nRadiation therapy\", \"percent\": \"20%\", \"answer\": \"Radiation therapy can be used as an adjunctive treatment for intramedullary spinal cord tumors, but it is not the first-line treatment.\"}, {\"option\": \"C\\nChemotherapy\", \"percent\": \"10%\", \"answer\": \"Chemotherapy is not typically the first-line treatment for intramedullary spinal cord tumors. It may be used in certain cases, but surgical resection is usually the initial treatment.\"}, {\"option\": \"D\\nSurgical resection\", \"percent\": \"50%\", \"answer\": \"Surgical resection is the treatment of choice for intramedullary spinal cord tumors. These tumors are typically slow-growing and well-circumscribed, making them amenable to surgical resection.\"}, {\"option\": \"E\\nObservation\", \"percent\": \"5%\", \"answer\": \"Observation is not appropriate in this case. This patient has progressive neurological symptoms that are likely due to the intramedullary spinal cord tumor. Treatment is necessary to prevent further neurological deterioration.\"}], \"correct_answer\": \"D\\nSurgical resection\\n50%\\nSurgical resection is the treatment of choice for intramedullary spinal cord tumors. These tumors are typically slow-growing and well-circumscribed, making them amenable to surgical resection.\", \"tag\": \"neurology,neurosurgery\"}\n",
            "\n",
            "The correct answer is \"Surgical resection\" because the patient's presentation and biopsy results are consistent with an intramedullary spinal cord tumor, likely an ependymoma. These tumors are typically slow-growing and well-circumscribed, making them amenable to surgical resection.\n",
            "\n",
            "The other options are incorrect for the following reasons:\n",
            "\n",
            "- \"High-dose corticosteroids\" can be used to reduce edema and inflammation in the spinal cord, but they are not the definitive treatment for an intramedullary spinal cord tumor.\n",
            "\n",
            "- \"Radiation therapy\" can be used as an adjunctive treatment for intramedullary spinal cord tumors, but it is not the first-line treatment.\n",
            "\n",
            "- \"Chemotherapy\" is not typically the first-line treatment for intramedullary spinal cord tumors. It may be used in certain cases, but surgical resection is usually the initial treatment.\n",
            "\n",
            "- \"Observation\" is not appropriate in this case. This patient has progressive neurological symptoms that are likely due to the intramedullary spinal cord tumor. Treatment is necessary to prevent further neurological deterioration.\n",
            "Output string has been stored in '/content/drive/My Drive/results/d5-ans/output_33.json.txt'\n",
            "\n",
            "\n",
            "Contents of 101.json:\n",
            "{'question': 'A 52-year-old woman comes to the physician because of swelling in her legs for the past 2 months. She has noticed that her legs gradually swell up throughout the day. She has hypertension and type 2 diabetes mellitus. Current medications include lisinopril and metformin. She works as a waitress at a local diner. Her father died of liver cancer at the age of 61 years. She drinks one to two glasses of wine daily and occasionally more on weekends. She does not smoke cigarettes or use illicit drugs. Vital signs are within normal limits. Examination shows 1+ pitting edema in both lower extremities up to the level of the calves with relative sparing of the feet. There are several dilated, compressible tortuous veins measuring 4–5 mm over both lower extremities, and multiple excoriation marks are noted over both ankles. There is a 2 x 2-cm ulcer with a shallow base and irregular edges over the medial surface of the left ankle. The lungs are clear to auscultation. Cardiac examination shows no murmurs, gallops, or rubs. The abdomen is soft and nontender; there is no organomegaly. Serum glucose, urea nitrogen, creatinine, D-dimer concentrations, and results of liver function tests are within the reference ranges. The ankle-brachial index is 1.1 bilaterally. Which of the following is the most appropriate next step in management?', 'hint': \"Lower extremity edema with relative sparing of the feet and dilated tortuous veins > 3 mm in diameter (varicose veins) in the absence of other systemic findings (e.g., pulmonary crackles, jugular venous distention) strongly suggests chronic venous disease (CVD), for which this patient's age, sex, and job that involves prolonged standing are risk factors. The presence of certain skin changes such as pruritic dermatitis or a venous ulcer indicates advanced CVD.\", 'options': [{'option': 'A\\nSclerotherapy', 'percent': '2%', 'answer': 'Sclerotherapy, which is a form of vein ablation therapy (VAT), is a treatment option for varicose veins. However, endovenous thermal ablation is preferred over sclerotherapy because of lower complication rates. Furthermore, another step is required before proceeding with VAT.', 'image': None}, {'option': 'B\\nClopidogrel and cilostazol therapy', 'percent': '4%', 'answer': 'Antiplatelet (e.g., clopidogrel) or vasodilator (e.g., cilostazol) therapy is not effective in the management of CVD. These drugs are primarily used in the management of peripheral artery disease (PAD), which can cause lower limb ulcers but such ulcers typically have regular margins and a punched-out appearance and occur over pressure points (e.g., tips of toes, lateral malleolus). Furthermore, PAD causes pale, shiny, cold, hairless skin on the lower extremities rather than edema and dermatitis and the normal ankle-brachial index (1.0–1.4) makes PAD extremely unlikely.', 'image': None}, {'option': 'C\\nDuplex ultrasonography', 'percent': '16%', 'answer': 'Current guidelines recommend that all patients suspected to have CVD should undergo duplex ultrasonography before any treatment. The goal is to identify whether the patient has a correctable cause of venous reflux (e.g., reflux in the superficial venous system), and to plan for an interventional procedure (e.g., by identifying the superficial, deep, and perforator vein sites) if the patient qualifies for such a procedure.\\n\\nAn initial trial of compression therapy is appropriate for patients with mild CVD (i.e., varicose veins or edema only) without a correctable cause, and pregnant patients with CVD. A patient with advanced CVD, as seen here, or a correctable cause of venous reflux should undergo endovenous thermal ablation as long as there are no contraindications to the procedure (e.g., deep vein thrombosis, peripheral artery disease). All patients with CVD should be counseled on lifestyle changes to improve venous return (e.g., daily exercise, frequent elevation of the legs, avoidance of long periods of standing and sitting).\\nChronic venous disease', 'image': None}, {'option': 'D\\nCompression stocking therapy', 'percent': '72%', 'answer': 'Compression therapy (e.g., with compression stockings) provides symptomatic relief in patients with CVD. An initial trial of compression therapy is appropriate for patients with mild CVD (i.e., varicose veins or edema only) without a correctable cause, and pregnant patients with CVD. This patient has advanced CVD, for which a different treatment is indicated. Regardless of the severity, current guidelines recommend that any form of treatment should be preceded by another step.', 'image': None}, {'option': 'E\\nContrast venography', 'percent': '6%', 'answer': 'For patients with CVD, studies such as venography or venous plethysmography are not routinely recommended. These studies are only considered if the initial imaging modality is inconclusive or in specific circumstances (e.g., surgical planning for CVD due to intraabdominal venous obstruction).', 'image': None}], 'correct_answer': 'C\\nDuplex ultrasonography\\n16%\\nCurrent guidelines recommend that all patients suspected to have CVD should undergo duplex ultrasonography before any treatment. The goal is to identify whether the patient has a correctable cause of venous reflux (e.g., reflux in the superficial venous system), and to plan for an interventional procedure (e.g., by identifying the superficial, deep, and perforator vein sites) if the patient qualifies for such a procedure.\\n\\nAn initial trial of compression therapy is appropriate for patients with mild CVD (i.e., varicose veins or edema only) without a correctable cause, and pregnant patients with CVD. A patient with advanced CVD, as seen here, or a correctable cause of venous reflux should undergo endovenous thermal ablation as long as there are no contraindications to the procedure (e.g., deep vein thrombosis, peripheral artery disease). All patients with CVD should be counseled on lifestyle changes to improve venous return (e.g., daily exercise, frequent elevation of the legs, avoidance of long periods of standing and sitting).\\nChronic venous disease\\nGIVE FEEDBACK', 'tag': 'family-medicine-and-general-practice,cardiovascular-medicine,geriatrics'}\n",
            "The correct answer is \"Duplex ultrasonography\" because the patient's symptoms (lower extremity edema, varicose veins, and a venous ulcer) suggest chronic venous disease (CVD). Duplex ultrasonography is recommended for all patients suspected of having CVD to identify any correctable cause of venous reflux and to plan for an interventional procedure if the patient qualifies for such a procedure.\n",
            "\n",
            "Option A, \"Sclerotherapy,\" is incorrect because although it is a treatment option for varicose veins, endovenous thermal ablation is preferred due to lower complication rates. Furthermore, duplex ultrasonography should be performed before any treatment.\n",
            "\n",
            "Option B, \"Clopidogrel and cilostazol therapy,\" is incorrect because these drugs are primarily used in the management of peripheral artery disease (PAD), not CVD. The patient's symptoms and normal ankle-brachial index make PAD extremely unlikely.\n",
            "\n",
            "Option D, \"Compression stocking therapy,\" is incorrect because although it provides symptomatic relief in patients with CVD, it is only appropriate for patients with mild CVD without a correctable cause. This patient has advanced CVD, for which a different treatment is indicated.\n",
            "\n",
            "Option E, \"Contrast venography,\" is incorrect because it is not routinely recommended for patients with CVD. It is only considered if the initial imaging modality is inconclusive or in specific circumstances.\n",
            "<class 'str'>\n",
            "{\"question\": \"A 45-year-old man comes to the physician because of a 3-month history of swelling in his legs. He has a history of hypertension and hyperlipidemia. Current medications include lisinopril and atorvastatin. He works as a security guard and is often on his feet for long hours. His father died of a heart attack at the age of 60 years. He drinks alcohol occasionally and does not smoke cigarettes or use illicit drugs. Vital signs are within normal limits. Examination shows 2+ pitting edema in both lower extremities up to the level of the knees. There are several dilated, tortuous veins measuring 3–4 mm over both lower extremities. The lungs are clear to auscultation. Cardiac examination shows no murmurs, gallops, or rubs. The abdomen is soft and nontender; there is no organomegaly. Serum glucose, urea nitrogen, creatinine, D-dimer concentrations, and results of liver function tests are within the reference ranges. The ankle-brachial index is 1.2 bilaterally. Which of the following is the most appropriate next step in management?\", \"hint\": \"Lower extremity edema with dilated tortuous veins (varicose veins) in the absence of other systemic findings (e.g., pulmonary crackles, jugular venous distention) strongly suggests chronic venous disease (CVD), for which this patient's age, sex, and job that involves prolonged standing are risk factors.\", \"options\": [{\"option\": \"A\\nSclerotherapy\", \"percent\": \"5%\", \"answer\": \"Sclerotherapy, which is a form of vein ablation therapy (VAT), is a treatment option for varicose veins. However, endovenous thermal ablation is preferred over sclerotherapy because of lower complication rates. Furthermore, another step is required before proceeding with VAT.\"}, {\"option\": \"B\\nClopidogrel and cilostazol therapy\", \"percent\": \"3%\", \"answer\": \"Antiplatelet (e.g., clopidogrel) or vasodilator (e.g., cilostazol) therapy is not effective in the management of CVD. These drugs are primarily used in the management of peripheral artery disease (PAD), which can cause lower limb ulcers but such ulcers typically have regular margins and a punched-out appearance and occur over pressure points (e.g., tips of toes, lateral malleolus). Furthermore, PAD causes pale, shiny, cold, hairless skin on the lower extremities rather than edema and dermatitis and the normal ankle-brachial index (1.0–1.4) makes PAD extremely unlikely.\"}, {\"option\": \"C\\nDuplex ultrasonography\", \"percent\": \"80%\", \"answer\": \"Current guidelines recommend that all patients suspected to have CVD should undergo duplex ultrasonography before any treatment. The goal is to identify whether the patient has a correctable cause of venous reflux (e.g., reflux in the superficial venous system), and to plan for an interventional procedure (e.g., by identifying the superficial, deep, and perforator vein sites) if the patient qualifies for such a procedure.\"}, {\"option\": \"D\\nCompression stocking therapy\", \"percent\": \"10%\", \"answer\": \"Compression therapy (e.g., with compression stockings) provides symptomatic relief in patients with CVD. An initial trial of compression therapy is appropriate for patients with mild CVD (i.e., varicose veins or edema only) without a correctable cause. This patient has advanced CVD, for which a different treatment is indicated.\"}, {\"option\": \"E\\nContrast venography\", \"percent\": \"2%\", \"answer\": \"For patients with CVD, studies such as venography or venous plethysmography are not routinely recommended. These studies are only considered if the initial imaging modality is inconclusive or in specific circumstances (e.g., surgical planning for CVD due to intraabdominal venous obstruction).\"}], \"correct_answer\": \"C\\nDuplex ultrasonography\\n80%\\nCurrent guidelines recommend that all patients suspected to have CVD should undergo duplex ultrasonography before any treatment. The goal is to identify whether the patient has a correctable cause of venous reflux (e.g., reflux in the superficial venous system), and to plan for an interventional procedure (e.g., by identifying the superficial, deep, and perforator vein sites) if the patient qualifies for such a procedure.\", \"tag\": \"family-medicine-and-general-practice,cardiovascular-medicine,geriatrics\"}\n",
            "Output string has been stored in '/content/drive/My Drive/results/d5-ans/output_101.json.txt'\n",
            "\n",
            "\n"
          ]
        }
      ],
      "source": [
        "import os\n",
        "import json\n",
        "\n",
        "folder_path = '/content/drive/MyDrive/amboss_tag/d5'  # Replace with your folder path in Google Drive\n",
        "starting_file = '1.json'\n",
        "file_list = os.listdir(folder_path)\n",
        "\n",
        "# Sort the file list to ensure consistent order\n",
        "#file_list.sort()\n",
        "\n",
        "# Function to read JSON files in a folder\n",
        "def read_json_files(folder_path):\n",
        "    json_contents = {}\n",
        "    if starting_file in file_list:\n",
        "    # Find the index of the starting file\n",
        "      start_index = file_list.index(starting_file)\n",
        "\n",
        "    # Process files from the starting file onward\n",
        "      for file_name in file_list[start_index:]:\n",
        "        file_path = os.path.join(folder_path, file_name)\n",
        "        with open(file_path, 'r') as file:\n",
        "                json_contents[file_name] = json.load(file)\n",
        "    return json_contents\n",
        "\n",
        "# Accessing JSON files in the specified folder\n",
        "json_data = read_json_files(folder_path)\n",
        "\n",
        "t = 0\n",
        "# Print contents of each JSON file\n",
        "for file_name, data in json_data.items():\n",
        "    print(f\"Contents of {file_name}:\")\n",
        "    print(data)\n",
        "    original_question = json.dumps(data)\n",
        "    data1 = prompt1(original_question)\n",
        "    fin_question = prompt2(original_question, data1)\n",
        "    folder_path = '/content/drive/My Drive/results/d5-ans'  # Replace with your folder path in Google Drive\n",
        "    os.makedirs(folder_path, exist_ok=True)\n",
        "    file_name = f\"output_{file_name}.txt\"  # File name\n",
        "    # Join folder path and file name\n",
        "    file_path = os.path.join(folder_path, file_name)\n",
        "    # Store the string into a text file\n",
        "    with open(file_path, 'w') as file:\n",
        "      file.write(fin_question)\n",
        "\n",
        "    print(f\"Output string has been stored in '{file_path}'\")\n",
        "    print(\"\\n\")\n",
        "    t = t+1\n",
        "    if t>8:\n",
        "      break"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "H1dZ5rhgFPF-"
      },
      "outputs": [],
      "source": []
    }
  ],
  "metadata": {
    "colab": {
      "provenance": []
    },
    "kernelspec": {
      "display_name": "Python 3",
      "name": "python3"
    },
    "language_info": {
      "name": "python"
    }
  },
  "nbformat": 4,
  "nbformat_minor": 0
}